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INTRODUCTION 
Diseases affecting muscles and the neuromuscular junction are commonly 
overlooked when evaluating a dog with lameness. Orthopedic disorders occur 
more frequently than neuromuscular disorders; however, when a diagnosis cannot 
be reached following a careful orthopedic evaluation, neuromuscular pathologic 
conditions should be considered (Shelton 2006). Poor attempts, especially in small 
animals, have been made to evaluate the prevalence of neuromuscular disorders in 
veterinary medicine, whereas various studies explore their epidemiology in 
specific geographic areas (Emery et al. 1991; Merlini et al. 1992; Hughes et al. 
1996; Darin & Tulinius 2000; Aleman 2008; Graziano et al. 2015). 
The clinical signs of neuromuscular disease can be enigmatic. The cardinal sign of 
neuromuscular disease is weakness, but some neuromuscular diseases do not 
exhibit weakness, whereas a number of non-neuromuscular diseases will present 
with weakness as major clinical feature (Amann 1987). Affected individuals with 
muscle or neuromuscular junction disease may present with lameness, limb 
contractures or more generalized musculoskeletal abnormalities, such as a 
crouched stance and stiff, short-stridden gait. Muscle tone and peripheral reflexes 
are normal or reduced and there may be significant muscle atrophy in chronic 
myopathies. In some individuals, weakness of the pharyngeal, laryngeal and 
esophageal muscles may result in dysphagia, dysphonia or regurgitation. Pyrexia 
may be present in inflammatory myopathies or be associated with aspiration 
pneumonia as a result of mega-esophagus (Shelton 2006). 
In human medicine, the approach to the diagnosis of myopathies follows a well-
determined algorithm. In presence of proximal muscle weakness and atrophy, 
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early fatigue and/or presence of flexural deformities simple musculoskeletal 
pathologies are ruled out with clinical and radiographical evaluation. Then firstly, 
serum muscle markers are determined: if they result raised compared to the 
physiological threshold a muscular disorder should be considered. 
Electromyography (EMG) and nerve conduction studies (NCS) are the most 
useful to exclude denervation disorders. In congenital myopathies, the EMG is 
typically normal or shows myopathic features, but occasionally EMG changes that 
appear neurogenic can be seen with severe neonatal weakness or in distal muscles 
later in the disease course. Nerve conduction studies are normal (North et al. 
2014). Specific investigations such as repetitive nerve stimulation or single fibre 
EMG are important to exclude myasthenic syndromes, although some congenital 
myopathies can be associated with neuromuscular junction abnormalities. 
Investigations other than muscle biopsy are rarely specific for myopathies, but are 
widely used to exclude other possible diagnoses. Imaging techniques, such as 
radiographs, computed tomography or resonance magnetic imaging, and 
ultrasound have assumed increasing importance in the diagnostic approach for 
patients with muscle disease and show specificity for several genetic entities. The 
degree of involvement of the muscle can be suspected on clinical grounds, it may 
be very helpful to utilize muscle imaging (MRI, ultrasound, or CT) to estimate the 
degree of involvement. MRI should be regarded as a gold standard technique 
(Bönnemann et al 2014). 
Indeed, over recent years muscle ultrasound and magnetic resonance imaging 
(MRI) have been increasingly used to differentiate between different forms of 
congenital myopathy. Selective muscle involvement on MRI can be suggestive of 
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a specific disease gene, however the specificity is variable and imaging is usually 
interpreted in conjunction with clinical phenotype and results of muscle biopsy to 
prioritize gene testing. In the future, once data has been collected to determine the 
specificity of patterns of muscle involvement muscle MRI may be used in 
conjunction with clinical features to guide genetic testing prior to muscle biopsy 
when a congenital myopathy is suspected. Muscle ultrasound is a practical way to 
image muscle that does not require general anaesthetic and can be performed at 
the bedside. However its utility is dependent on the expertise and experience of 
the ultrasonographer. Muscle ultrasound can also be helpful in recognising 
possibly neurogenic changes and in selecting an appropriate muscle for biopsy. 
(North et al. 2014) 
In veterinary clinical practice, the simplest and most routine diagnostic test for 
muscle disease is blood chemistry. A complete blood cell count, serum chemistry 
panel (including creatine kinase levels and electrolytes), and urinalysis should be 
evaluated in every animal with a suspected neuromuscular disease. (Glass & Kent 
2002) 
 Enzyme activities that may be increased due to muscle disease are aspartate 
transaminase (AST/GOT), creatine kinase (CK/CPK), and lactate dehydrogenase 
(LD/LDH). These intracellular enzymes are released when the muscle cell 
membrane is injured. They are specific for diseases that affect the muscle cell 
portion of the motor unit. The half-life of these enzymes in the blood is specific 
for each markers so that an increased activity can be a good indicator not only of a 
muscle damage but also of the its duration. The half-life of CK is only a few 
hours, whereas that of AST is several days. A number of cautions are necessary to 
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prevent misinterpretation of increased activity of muscle enzymes. When 
available, muscle biopsy remains the most useful diagnostic tool in the diagnosis 
of muscle disease, both in human and in veterinary medicine. Nerve biopsy can 
also be performed on either mixed or sensory peripheral nerves with little effect 
on the performance of an animal. This can be useful in the diagnosis of peripheral 
nerve disease. As in human medicine, in animals EMG studies represent the state 
of the art in neuromuscular diagnostic techniques. EMG can be performed to 
determine the nerve conduction velocity (sensory or motor), the presence of 
abnormal electrical activity in muscle (due to denervation, inflammation, or 
hyperexcitability of the muscle cell membrane), and the ability of the synapse to 
function (evoked motor action potentials and the decremental response) (Amann 
1987). 
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ANATOMY AND PHYSIOLOGY 
A typical neuron has four morphologically defined regions: the dendrites, the cell 
body, the axon, and the presynaptic terminals of the axon. These four anatomical 
regions are important in the major electrical and chemical responsibilities of 
neurons: receiving signals from the presynaptic terminals of other neurons (on 
dendrites), integrating these often-opposing signals (on the initial segment of the 
axon), transmitting action potential impulses along the axon, and signaling an 
adjacent cell from the presynaptic terminal. The cell body (also called the soma or 
perikaryon) plays a critical role in manufacturing proteins essentials for neuronal 
function. The cell body usually gives rise to several branchlike extensions, called 
dendrites, whose surface area and extent greatly exceed those of the cell body. 
The dendrites serve as the major receptive apparatus of the neuron, receiving 
signals from neighboring neurons. The cell body also gives rise to the axon, a 
tubular process that is often long. The axon is the conducting unit of the neuron, 
rapidly transmitting an electrical impulse (the action potential) from its initial 
segment at the cell body to the other and of the axon at the presynaptic terminal. 
Large axons are surrounded by a fatty, insulating coating called myelin. In the 
peripheral nervous system, myelin is formed by Schwann cells. The myelin sheath 
is interrupted at regular intervals by spaces called nodes of Ranvier. Axons branch 
near their ends into several specialized endings called presynaptic terminals. 
When the action potential rapidly arrives, these presynaptic terminals transmit a 
chemical signal to an adjacent cell, usually another neuron or a muscle cell. The 
site of contact of the presynaptic terminal with the adjacent cell is called the 
synaps. It is formed by the presynaptic terminal of one cell (presynaptic cell), the 
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receptive surface of the adjacent cell (postsynaptic cell), and the space between 
these two cells (the synaptic cleft). The receptive surface of the postsynaptic cell 
contains specialized receptors for the chemical transmitter released from the 
presynaptic terminal. Neurons, as with other cells of the body, have an electrical 
potential, or voltage, that can be measured across their cell membrane (resting 
membrane potential). The resting membrane potential is the result of the 
differential separation of charged ions, especially sodium (Na
+
) and potassium 
(K
+), across the membrane and the resting membrane’s differential permeability to 
these ions as they attempt to move back down their concentration and electrical 
gradients. 
The neuromuscular synapse, also known as neuromuscular junction is a chemical 
synapse between a motor neuron and a skeletal muscle cell (fiber). The 
presynaptic side of the synapse is made up of the terminal portion of the motor 
neuron. This presynaptic terminal has a swelled, button-like appearance and is 
also called a synaptic bouton. The synaptic bouton contains a large number of 
membranous storage vescicles, called synaptic vescicles, which contain the 
chemical neurotransmitter substance, in this case acetylcholine. Directly opposite 
the face of the presynaptic terminal, the postsynaptic muscle cell membrane 
contains receptor for the acetylcholine transmitter. In this focal region the 
membrane has a series of invaginations, called junctional folds, that increase the 
surface area where acetylcholine receptors can reside. Because the 
neurotransmitter is found only on the presynaptic neural side of the 
neuromuscular junction, transmission can go only from neuron to muscle, not in 
the reverse direction. The function of the neuromuscular junction is to transmit a 
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chemical message unidirectionally between a motor neuron and a skeletal muscle 
cell (fiber) with a frequency established by the central nervous system. The arrival 
of an action potential at the motor neuron terminal triggers the release of the 
acetylcholine transmitter, which then binds with acetylcholine receptors on the 
postsynaptic muscle fiber membrane. This leads to the genesis of an action 
potential along the muscle fiber membrane that ultimately leads to contraction of 
the fiber.  
All body movement is the result of contraction of skeletal muscle. When activated 
by a motor nerve, a skeletal muscle can only shorten. Each muscle belly is made 
up of differing numbers of muscle fibers, the outer limiting membrane of the fiber 
is called sarcolemma that consists of a true cell membrane, called the plasma 
membrane, and of an outer polysaccharide layer that attaches to the tendons at the 
cells’ extremities. Each muscle fiber is innervated by only one motor neuron, with 
the neuromuscular junction region located near the middle of the fiber, relative to 
the ends. Each fiber contains several hundred to several thousand myofibrils 
arranged in parallel along its length and each myofibril is made up of a linear 
series of repeating sarcomeres, the basic contractile units of the muscle fiber. The 
sarcomere has a disk at each end, called Z disk. The sarcomere contains four types 
of large protein molecules responsible for muscular contraction, three of which 
are polymerized. Numerous thin protein filaments, called actin, are attached to the 
Z disks and extend toward the center of the sarcomere. Each actin filament 
consists of two intertwined, helical strands of actin protein and two such strands 
of tropomyosin protein, all bound together as a larger helical complex. Also 
located intermittently along the tropomyosinactin strand are complex globular 
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protein molecules called troponin that can bind tropomyosin and actin and that 
have an affinity for calcium (Ca
2+
) ions. Suspended between and parallel to the 
actin thin filaments are thicker filaments of myosin protein polymers. A myosin 
molecule contains a tail of intertwined helices and two globular heads that can 
bind both adenosine triphosphate (ATP) and actin. Beneath the plasma membrane 
of the muscle cell lies the sarcoplasmatic reticulum, an intracellular storage 
organelle that forms a reticulated network around the myofibrils. This extensive 
storage sac sequesters Ca
2+ 
ions in relaxed muscle and is analogous to the smooth 
endoplasmic reticulum in other cells. Located perpendicular to the long axis of the 
muscle fiber, there are tubes of plasma membrane formed by periodic 
invaginations of the sarcolemma. These transverse tubules, or T tubules, traverse 
the diameter of the muscle fiber. The T tubules snake around the myofibrils, 
forming junctions with the network of sarcoplasmic reticulum that surrounds the 
myofibrils. These tubules are filled with extracellular fluid and are important 
because they allow the electrically excitable plasma membrane of the muscle fiber 
to carry the depolarization of the action potential to the interior of the fiber. 
Skeletal muscle cells have resting membrane potential, as do neurons, and the 
muscle cell membrane can be depolarized by synaptic transmission at the 
neuromuscular junction. At this junction, the acetylcholine released by the motor 
neuron activates nicotinic acetylcholine receptors on the sarcolemma of the 
muscle cell. The resulting depolarization is sufficient to open enough voltage-
gated Na
+
 ion channels, also found at the junctional sarcolemma, to trigger a 
muscle fiber action potential. Thus, it is at the sarcolemma of the neuromuscular 
junction that muscle fiber action potentials are generated. Once an action potential 
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is generated near the midpoint of the muscle fiber, it spreads in both directions 
along the length of the fiber. The action potentials are also transmitted to the 
interior of the muscle fiber along the T tubules. This allows the action potential to 
reach the location of the sarcoplasmatic reticulum even in the innermost regions 
of the muscle fiber. 
The sarcomere is changed from its relaxed state to the shorter, contracted state 
when Ca
2+
 ions become available to the sarcomere. In the presence of Ca
2+
 ions 
and a sufficient source of ATP, the actin thin filaments are pulled in parallel along 
the myosin thick filaments by the repetitive movement of the myosin molecule 
heads, thus shortening the sarcomere. Because each myofibril is made up of a 
linear series of repeating and connected sarcomeres, the net result is the physical 
shortening of the distance between the two ends of the muscle: the muscular 
contraction. (Cunningham et al. 2007) 
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DEFINITION 
The term “neuromuscular disease” refers to a broad category of pathologic 
conditions affecting nerve and/or muscle. Amann (1987) define neuromuscular 
disease as any entity that interferes with the normal structure and function of the 
motor unit. Neuromuscular diseases can be conveniently classified and studied 
according to the part (or parts) of the motor unit on which the disease’s primary 
effect is exerted (Amann 1987). 
The neuromuscular system is a conduit for transmission of information from the 
central nervous system to the musculoskeletal system. Consequently, an 
abnormality in any portion of the lower motor unit can result in clinical signs of 
neuromuscular disease (Glass et al. 2002). For instance, neuropathies affect some 
aspect of the motor neuron cell body, axon, or telodendron. Spinal muscular 
atrophies affect the cell bodies located in the gray matter of the spinal cord; these 
conditions may also be termed motor neuron or ventral horn cell diseases. 
Radiculopathies affect the axons or their myelin sheaths in the spinal roots, 
whereas peripheral neuropathies affect the axon, its telodendron, or the myelin 
sheath in the peripheral nerve and muscle. When a pathologic process initially 
affects the telodendron or distal axon, it may be referred to as a dying back 
disease. Diseases that affect the neuromuscular termination are referred to as 
junctionopathies. A myopathy is a neuromuscular disease that primarily affects 
the muscle itself. Those diseases that have primary effects on both nerve and 
muscle are referred to as neuromyopathies. Any disease of any part of the motor 
unit will be reflected in a partial or complete loss of function in the muscle itself. 
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Muscle that is removed from the trophic influence of its motor neuron undergoes 
atrophy (termed neurogenic atrophy) (Amann 1987). 
Neuromuscular disease may be either congenital or acquired. Congenital 
neuromuscular disease is any disease that an animal is born with or acquires as a 
result of some factor relating to birth. It may be an inherited entity or the effect of 
some in utero influence. Acquired neuromuscular disease is more common than 
congenital disease and often affects older dogs (Amann 1987). 
Inherited peripheral neuropathies in dogs and cats have rarely been documented, 
and the mode of inheritance often can only be speculated. Furthermore, the 
specific genetic defect has not been identified for any inherited peripheral 
neuropathy in pets. These neuropathies can affect autonomic nerves, sensory 
nerves, and motor fibers alone or in combination (Coates et al. 2004).  
Inherited peripheral neuropathies are classified as motor and sensory (mixed) 
neuropathies, primary sensory neuropathies, and neuropathies related to inborn 
errors of metabolism, including storage disorders. Pathologic studies further 
subdivide mixed and primary sensory neuropathies into those that affect the 
central nervous system (CNS) and the peripheral nervous system (PNS) as in 
central-peripheral distal axonopathy and those limited to the PNS. The latter are 
further subdivided into myelinopathies or axonopathies (Coates et al. 2004). 
Muscle disease may be subdivided into six broad categories on the basis of sets of 
fairly distinctive clinicopathologic characteristics: atrophies, dystrophies, 
inflammatory myopathies, metabolic myopathies, "congenital" myopathies, and 
disorders of neuromuscular transmission (De Girolami et al. 1982). 
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DIAGNOSTIC TOOLS 
A diagnostic plan for an animal with suspected neuromuscular disease should 
include a complete neurologic examination and minimum database (complete 
blood count [CBC], serum biochemistry panel, urinalysis, thoracic radiographs, 
and abdominal ultrasound). Electrophysiologic evaluation and muscle/nerve 
biopsies are essential considerations in the accurate diagnosis of most diseases 
affecting the neuromuscular system. 
Specific abnormalities include anemia, hypo- and hyperglycemia, hypo- and 
hyperkalemia, hypo- and hypernatremia, hypo- and hypercalcemia, 
hypophosphatemia, and hypomagnesemia. If not part of the biochemical panel, 
serum creatine kinase (CK) activity should be measured. In addition, baseline 
testing in any dog or cat with clinical neuromuscular disease should include 
measurement of serum cardiac troponin I and plasma lactate concentrations and 
determination of thyroid status (Shelton 2010). 
CBC may reveal abnormalities, such as a stress leukogram supportive of 
hyperadrenocorticism or a mild normocytic, normochromic, non-regenerative 
anemia supportive of hypothyroidism. The chemistry panel may reveal electrolyte 
abnormalities, ionic imbalances, and blood glucose aberrations, which may be 
responsible for myopathic signs (Platt et al. 2004). 
Muscle enzymes are often isoenzymes of enzymes that occur in other tissue as 
well. The enzymes aspartate aminotransferase (AST) and lactate dehydrogenase 
(LDH) are also present in hepatocytes, and these two plus creatine kinase (CK) 
are present in cardiac muscle (Amann 1987; Blot 2005).  
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Evaluation of serum CK concentration should be a part of the neuromuscular 
minimum database and may be indicative of active muscle disease in canine and 
feline patients. In muscle, CK functions in making ATP available for muscle 
contraction by the phosphorylation of ADP from creatine phosphate. The serum 
half-life of CK is short, lasting only 6 hours; a persistent elevation of four to five 
times the normal level in two tests performed between 24 and 48 hours of each 
other is an indication of a recent and active muscle lesion. CK may be normal in 
the presence of muscle disease, thus muscle diseases should not be ruled out based 
on a normal CK concentration. Serum CK may also be mildly elevated in the 
absence of neuromuscular disease related to factors like exercise, recumbency, or 
trauma (e.g., needle injections) or markedly elevated in anorexic cats. Elevations 
of CK are most dramatic in the muscular dystrophies or with myonecrosis (100 
times normal); moderately elevated in inflammatory myopathies (10 times 
normal); or normal or only mildly elevated in other diseases, such as myotonia 
congenita. Elevated levels of serum AST, and LDH can also be compatible with 
muscle disease; however, as is the case for CK, they are not disease specific and 
can be normal in some myopathies (Platt et al. 2004). 
CK and AST have very different kinetics, which need to be taken into 
consideration when diagnosing the extent and time frame of muscle damage. AST 
takes up to 24 hours to peak and several days to return to baseline. CK tends to be 
used for acute monitoring of muscle enzymes and AST for evaluation of changes 
over a longer period (Moses et al. 2007).  
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CK activity in blood is ultimately the most useful muscle enzyme measurement 
and can be used to follow the course of a muscle disease as well as monitor 
response to treatment or exacerbation of the disease (Amann 1987) 
However, tremendous variability occurs, based on age (the younger the animal, 
the higher the value), breed (the smaller the dog, the higher the value), motor 
activity (exercise produces higher value), recent intramuscular injections, and 
sampling methods. Although some myopathies are associated with dramatic 
persistent elevations, numerous myopathies cause little, transient, or no elevation 
at all. Therefore, as previously stated, a normal CK level should not exclude a 
muscle disease from the differential diagnosis (Blot 2005). 
Intramuscular injections of drugs can cause an increase in CK activity with a peak 
at about 4 hours, consistent increase for about 24 hours, and return to baseline by 
the third day. Serum CK activity can be increased as much as 12-fold in animals 
in prolonged recumbency and can also be increased during and after surgery, 
peaking within 6 to 12 hours. Electromyographic procedures can result in 
increased activity. Anorexia in cats may be associated with moderate to marked 
increases in serum CK activity and should not be considered diagnostic of 
myopathy until feeding has resumed. If the serum CK activity is persistently 
increased and external causes can be eliminated, an underlying neuromuscular 
disease should be considered (Shelton 2010). 
Specific blood tests include a corticotropin stimulation test in combination with an 
endogenous corticotropin assay for hyper- and hypoadrenocorticism; a 
combination of serum total thyroxin (T4), an endogenous thyroid-stimulation 
hormone (TSH) assay, and free T4 levels for hypothyroidism; and serum antibody 
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titers for infectious diseases, such as Neospora caninum and Toxoplasma Gondii. 
Arterial blood gas analysis performed before and after exercise normally reveals 
significant elevations of blood pH and PaO2, along with significant decreases in 
PaCO2 and bicarbonate concentrations. Although the anion gap can be expected to 
increase as well after a period of exercise, it does not reach clinically significant 
levels (Platt et al. 2004). 
Resting and post-exercise plasma lactate and pyruvate concentrations should be 
measured as a screening test in all animals with suspected myopathic causes of 
weakness and collapse, especially in those with signs related to activity. Although 
not as ideal, pre- and postprandial lactate and pyruvate analysis can be performed 
when rest and subsequent exercise of the patient are not possible. Blood for lactate 
concentration should be collected into sodium fluoride/potassium oxalate tubes, 
and the plasma should be separated and stored at -20°C until it can be analyzed. 
Blood for pyruvate analysis should be mixed at a 1:1 ratio with 8% perchloric acid 
and centrifuged. The supernatant should be removed and kept frozen and analyzed 
within 30 days. Delays of more than 1 hour or more before deproteinization of 
samples can induce major elevations of the lactate/pyruvate (L/P) ratios. 
Evaluation of plasma lactate, pyruvate, and their molar (L/P) ratio can provide 
important information in the evaluation of possible metabolic myopathies and is 
critical for the diagnosis of mitochondrial diseases. Lactate and pyruvate readily 
diffuse from working muscles, and levels of these metabolites in venous blood 
can be used to monitor the integrity and level of activation of the energy pathways 
from which they arise. Although not fully characterized in veterinary medicine, 
the L/P ratio may provide a preliminary subclassification of a possible metabolic 
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disorder. The level of these muscle metabolites in venous blood after exercise is 
also a function of the intensity of work performed. A control animal exercised at a 
similar relative intensity is necessary for valid comparison. Lactic acidemia is a 
hallmark of mitochondrial myopathies and has been described in human beings 
and dogs. When a defect is present in either the pyruvate dehydrogenase complex 
or the electron transport chain, pyruvate is metabolized to either lactate, by lactate 
dehydrogenase, or to alanine, by alanine aminotransferase, resulting in lactic 
acidemia and hyperalaninemia. Documentation of a high serum lactate and 
pyruvate concentration with a normal L/P ratio is consistent with a defect in 
pyruvate dehydrogenase or one of the gluconeogenic enzymes. When lactic 
acidosis is found in association with a high L/P ratio, there is the possibility of an 
underlying defect of the mitochondrial electron transport chain or pyruvate 
decarboxylase deficiency. Specific respiratory chain defects giving rise to lactic 
acidemia can be demonstrated in mitochondrial preparations from cultured skin 
fibroblasts, but this requires expert laboratory assistance and is not performed on a 
routine basis (Platt et al. 2004). 
Diseases that affect skeletal muscle can also affect cardiac muscle. 
Cardiomyopathy has been convincingly demonstrated in muscular dystrophies 
(MD), mitochondrial myopathies, and, most recently, in a dog with severe 
necrotizing myopathy and in horses with atypical myopathy. Troponin is located 
primarily in myofibrils and is the regulatory protein of contractile skeletal and 
cardiac muscle, regulating the interactions of actin and myosin in muscle 
contraction. Troponin is composed of 3 subunits: troponin C, the calcium binding 
subunit; troponin I, the inhibitory component; and troponin T, the tropomyosin-
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binding subunit. Genes distinct from those encoding skeletal muscle isoforms 
encode cardiac troponin I, and this troponin is a marker of myocardial cellular 
injury. Thus, cardiac troponins are more specific for cardiac damage, compared 
with the specificity of LDH or CK activity or myoglobin concentration. 
Furthermore, cardiac troponin concentrations are generally not affected by 
nonspecific types of skeletal muscle damage, including trauma, IM injections, or 
strenuous exercise. Following myocardial damage, troponin I increases in 3–6 
hours, peaks at 14–20 hours, and returns to normal in 5–7 days. Cardiac troponin I 
has largely replaced CK isoenzyme testing in people and may be of value for 
assessing myocardial damage in animals. The value of other possible new 
biomarkers, such as skeletal muscle troponin and fatty-acid-binding protein-3, in 
assessing muscle damage has not been fully evaluated in neuromuscular diseases 
affecting people and companion animals (Shelton 2010). 
Urinary organic acids can be quantified by gas chromatography–mass 
spectrometry. Organic acidurias are most commonly genetic inborn metabolic 
errors resulting in accumulation of non-metabolizable organic acids in tissues and 
biologic fluids. Numerous disorders causing these abnormalities have been 
described in human beings, and, recently, there have been several such disorders 
causing neurologic and neuromuscular clinical signs documented in dogs. The 
accumulating organic acids are excreted in urine in free or esterified forms. 
Analysis of the profile of the abnormal excreted compounds provides a basis for 
the diagnosis of the genetic disorder underlying the acidotic syndrome. 
Mitochondrial defects of β-oxidation can also result in increased urinary excretion 
of organic acids. Plasma amino acids can be quantified by automated column 
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chromatography. The analysis of several amino acid profiles can be useful in 
determining the cause of muscle metabolism disorders. These include alanine and 
hypoxanthine, which readily diffuse from working muscle into the venous blood 
as markers of the integrity and level of activation of the energy pathways from 
which they arise. These tests are only available at a few laboratories (Platt et al. 
2004).  
Muscle damage will result in the release of muscle enzymes and the muscle 
protein myoglobin into the blood (measured in the serum or plasma) and 
myoglobin is rapidly filtered by the kidneys and appears in the urine (making it 
appear dark red) (Moses et al. 2007). Myoglobinuria refers to excessive 
myoglobin in the urine, resulting in brown-colored urine, and indicates an 
abnormal pathophysiologic state usually in association with severe muscle 
damage and clinical signs of weakness and myalgia. Myoglobinuria is frequently 
associated with rhabdomyolysis, a severe form of myonecrosis. Recurrent 
myoglobinuria may be found in inherited metabolic myopathies, such as glycogen 
storage disorders, fatty acid oxidation disorders, and mitochondrial myopathies, 
and in MD. Myoglobinuria may also occur as an isolated event following trauma, 
exposure to drugs and toxins, infectious diseases, fever, and excessive work, and 
malignant hyperthermia syndrome. Myoglobinuria is one of the most frequent 
causes of pigment nephropathy and acute kidney injury. Brown urine may indicate 
>250 µg/mL myoglobin in urine. In general, urine myoglobin concentration is not 
more sensitive for the detection of neuromuscular disease than serum CK activity, 
and no clear correlation exists between the serum CK activity and urine 
myoglobin concentration (Shelton 2010). 
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Urine, plasma, and muscle concentrations of total, free, and esterified carnitine 
can be determined by radioisotopic enzyme assay. A complex metabolic 
equilibrium exists for the various carnitine and acylcarnitine fractions in the 
different body compartments, between tissue and extracellular fluid pools, and for 
the fractions of these pools excreted in urine. Therefore, analysis of carnitine 
metabolism requires the determination of free and esterified carnitine 
concentrations in plasma, urine, and muscle. The most complete information on 
carnitine status is gained from evaluation of total, free, and esterified forms of 
carnitine in all three compartments. Because muscle is the largest reservoir of 
carnitine in the body, it is muscle carnitine that binds to abnormal organic acids, 
with ultimate excretion in the urine. Thus, carnitine may be depleted in muscle but 
be increased or normal in the plasma. Evaluation of the complete carnitine status 
is necessary for rational therapeutics of primary or secondary disorders of 
carnitine metabolism (Platt et al. 2004). 
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ELECTROMYOGRAPHY 
By definition, electromyography (EMG) is the recording and study of insertional, 
spontaneous, and voluntary electric activity of muscle. In human beings, EMG is 
routinely performed on the awaken patient, where voluntary muscle contraction 
can be used to assess recruitment of additional motor units and interference 
patterns with increasing strength of muscle contraction. Because of the difficulty 
of patient compliance, awaken EMG is not routinely performed in small animals. 
Instead, most patients are evaluated under general anesthesia, where insertional 
activity and spontaneous muscle activity are primarily assessed (van Nes 1986; 
Cuddon 2002).  
All EMG testing is subject to technical difficulties because of external noise from 
other electric outlets (60-cycle interference) or anesthesia related equipment in the 
same room and ideally should be performed in a Faraday room. The animal 
should be placed on a padded surface, grounded to the machine and in a warm 
environment to prevent artifactual changes in results. Four major types of EMG 
recording electrodes are available. The two most commonly used in veterinary 
medicine are the concentric needle electrode and the monopolar needle electrode. 
The concentric (coaxial) needle electrode measures the potential difference 
between a nichrome, silver, or platinum wire and the stainless-steel shaft that 
surrounds it. Monopolar needle electrodes are composed of insulated stainless 
steel, except at the tip. Each of these types of recording electrodes has its 
advantages and disadvantages. The concentric needle electrode detects less 
background noise than monopolar needles, and it detects fibrillation potentials 
more often, because these potentials are most commonly induced by actual needle 
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insertion rather than occurring spontaneously. The fact that concentric needle 
electrodes cause more tissue damage than monopolar electrodes allows the 
detection of fibrillation potentials more easily. Monopolar electrodes are less 
electrically stable and noisier than concentric needle electrodes, although they do 
produce less pain and record a considerably larger potential from the same source 
than the concentric needle. The monopolar electrodes are also able to detect 
distant potentials as a result of their substantial interelectrode distance. Although 
surface electrodes are used in human beings, they are not suitable for veterinary 
use because of technical difficulties related to poor electrode–skin contact as a 
result of the presence of a hair coat. Bipolar concentric needle electrodes, the 
fourth electrode type, have been rarely used in veterinary medicine. No matter 
which electrode type is used, the sensitivity of the EMG examination is increased 
dramatically by increasing the number of evaluation sites (or passes) in each 
muscle and also by increasing the number of muscles examined. Abnormal 
spontaneous muscle activity is commonly a patchy phenomenon with 
considerable variation in location. Normal resting muscle is generally electrically 
silent.  
Four types of electric activity, however, may be seen in normal muscle: 
insertional activity, miniature end-plate potentials (MEPPs), end-plate spikes, and 
motor unit action potentials (MUAPs). Insertional activity can be used to 
determine muscle excitability. Normal insertion activity is produced by 
mechanical damage to the myofibers as a result of the action of needle placement, 
causing brief spontaneous bursts of electric activity that begin and end abruptly as 
the needle is placed (Fig. 1A). They consist of positive or negative high-frequency 
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spikes in a cluster. This produces a crisp static sound. In normal muscle, this 
activity should last a few hundred milliseconds depending on the speed and 
magnitude of electrode movement, with no indication of waxing and waning. It 
can be prolonged in disease states that cause instability of the muscle membrane 
such as denervation or inflammation and can be decreased in severe muscle 
atrophy or fibrosis caused by a decreased number of available myofibers. MEPPs 
represent low-amplitude electric activity in normal muscle caused by normal 
sustained random spontaneous release of single quanta of acetylcholine (ACh), 
resulting in depolarization at the postsynaptic membrane (see Fig. 1B). MEPPs are 
similar to the sound heard when listening inside a seashell. They usually have 5 to 
15 µV amplitude, although they can be as high as 50 µV. They have 1 to 2 
milliseconds duration. Because they do not result in depolarization of the entire 
myofiber, they are only seen if the recording electrode is placed in close proximity 
to an end plate. Diseases that decrease ACh release from the presynaptic 
membrane such as botulism produce MEPPs with normal amplitude but decreased 
frequency. Conversely, diseases such as myasthenia gravis that decrease binding 
of ACh postsynaptically cause decreased amplitude but normal frequency of 
MEPPs. Severe denervation results in a complete absence of MEPPs. A waveform 
that is commonly associated with MEPPs is the end-plate spike, which results 
from discharge of a single muscle fiber that is excited by activity in nerve 
terminals. These spikes occur intermittently, with an irregular firing rate of 5 to 50 
Hz and with an amplitude ranging from 100 to 300 µV.31 They have an initial 
negative (upward) deflection from baseline and are usually biphasic (Fig. 1B). 
Their appearance is similar to that of fibrillation potentials. MUAPs are seen only 
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with mild voluntary muscle contraction and represent isolated discharges from 
one or a few motor units (Fig. 1C). They represent a compound action potential of 
myofibers in the electrode’s recording range. These waveforms are generally 
biphasic or triphasic, with an initial negative peak. Amplitudes are variable but are 
usually in the range of 100 µV to 3 mV and fire at a rate of 5 to 7 Hz. They 
increase in frequency with increased activation of the same and new motor units, 
that is, with increasing strength of contraction (commonly termed recruitment). 
With maximum voluntary muscle contraction, there is a simultaneous discharge of 
many different MUAPs, precluding individual MUAP recognition (termed 
interference pattern). Patterns of MUAPs during maximal contraction are affected 
differently in various disease states. Myopathy produces a decrease in MUAP 
amplitudes but with normal density, whereas partial denervation results in a 
decreased density of MUAPs. The presence of many giant MUAPs (500 µV–5 
mV) would indicate reinnervation. These giant MUAPs are commonly 
polyphasic, because the new collateral nerve branches have thinner myelin sheaths 
than the established axons and thus have slower conduction velocities. As a result 
of poor patient compliance, evaluation of MUAPs and recruitment patterns is not 
used extensively in veterinary medicine. One area of application, however, is in 
the assessment of the severity and extent of peripheral nerve injury after trauma. 
The absence of any inducible MUAPs in a specific muscle with weight bearing 
(extensor muscle) or limb flexion (flexor muscle) would indicate severe nerve 
injury.  
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There are four patterns of abnormal spontaneous activity in EMG: fibrillation 
potentials, positive sharp waves, complex repetitive discharges (CRDs), and 
myotonic potentials.  
Fibrillation potentials and positive sharp waves represent the same underlying 
pathologic changes and differ in morphologic findings only in relation to their 
orientation to the recording electrode at the time of discharge. Both arise from 
spontaneously firing, hypersensitive, single myofibers as a result of 
destabilization of the sarcolemmal membrane. This can occur in denervation, 
polymyositis, muscular dystrophy, or other myopathies. Fibrillation potentials 
consist of biphasic or triphasic waves with the initial deflection usually in the 
positive (downward) direction, except if recorded within an end-plate region (Fig. 
2). These waves are 10 to 200 µV in amplitude and usually appear in bursts. They 
have the sound of frying eggs or the wrinkling of tissue paper.  
Positive sharp waves consist of an initial positive spike followed by a much 
shorter slow negative potential (Fig. 3A). These waveforms have a variable 
amplitude (50 µV–4 mV) and a much deeper sound than fibrillation potentials. 
They also represent irritated myofiber membrane, although unlike fibrillations, the 
potential stops at an area immediately adjacent to the recording electrode.  
CRDs are polyphasic repetitive waveforms with a uniform frequency, shape, and 
amplitude and represent spontaneous discharge of multiple myofibers firing in 
near synchrony (Fig. 3B and 3C). These trains of waves, with amplitudes in the 
range of 100 µV to 1 mV, can begin spontaneously or after needle movement and 
always have an abrupt onset and cessation. CRDs are more often associated with 
chronic denervation, although they are also seen in some myopathies such as that 
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associated with hyperadrenocorticism. These discharges are commonly mistaken 
for myotonic potentials.  
Myotonic potentials are the final abnormal spontaneous activity seen on EMG. 
These are repetitive discharges occurring at a rate of between 20 and 80 Hz, which 
must wax and wane over time. They represent independent repetitive discharges 
from single injured myofibers. The individual waveforms can be one of two types 
— either a sustained run of positive waves resembling positive sharp waves 
(PSWs) or a sustained run of biphasic spike potentials (an initial small positive 
peak followed by a larger negative peak) resembling fibrillation potentials. The 
waxing and waning nature of the frequency and amplitude of these waveforms 
produces the characteristic ‘‘dive-bomber’’ sound. This discharge is characteristic 
of myotonia congenita. There are a number of misconceptions concerning the 
amount of information that EMG alone can reveal about the extent and etiology of 
neuromuscular disease. EMG has limited value in: 
(1) Inferring clinical symptoms and neuropathic deficit, 
(2) Distinguishing between neuropathy and myopathy, 
(3) Inferring involvement of small-diameter fibers, 
(4) Inferring underlying biochemical or other pathophysiologic derangement,  
(5) Inferring the presence and type of pathologic alterations in single fibers and 
Schwann cells. 
Despite these limitations, EMG is clinically useful in differentiating between 
denervation atrophy and disuse muscle atrophy. This distinction may not always 
be evident historically or on physical examination, and this knowledge almost 
definitely alters therapy. EMG also has a high degree of sensitivity in detecting 
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peripheral nerve axonal loss, being able to detect abnormalities even when as few 
as 5% of the total number of axons in the nerve have been affected. It is important 
to remember, however, that any changes associated with denervation are not 
detected in dogs and cats for a minimum of 4 to 5 days after the initiating insult 
has occurred and that maximal changes are not seen until day 8 to 10. The first 
abnormality that is detected is an increase in insertional activity, followed closely 
by the presence of fibrillation potentials. Another factor that influences the delay 
time of fibrillations after injury is the distance from the injury site to the muscle, 
i.e. the shorter is the distance, the earlier the fibrillations appear. A significant 
decrease in the intensity of spontaneous activity over time is most commonly 
indicative of successful reinnervation; however, this phenomenon also can be seen 
with end-stage fibrosis. Mean values for serum CK in the dog do show increases 
after electrophysiologic evaluation, although they are still usually within the 
normal range. Dogs seem to be less sensitive to sarcolemmal damage from EMG 
electrodes compared with people. There is a delay, however, in this increase, with 
CK measurements immediately after EMG being unaffected. These CK values 
also return to normal by 48 hours after EMG examination (Cuddon 2002).  
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Figura 1 Types of electrical activity seen in normal muscle during EMG evaluation: A Insertional 
activity; B Miniature end-plate potentials with two end-plate spikes indicating close proximity 
of the needle to an end-plate; C  Motor unit action potentials seen during voluntary muscle 
activity in an awake animal. (Modified by Cuddon, 2002 
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Figura 2 Abnormal spontaneous electrical activity, in the form of fibrillation potentials, 
observed in muscle during EMG evaluation. A, Mild density of fibrillation potentials (50 V/div; 
10 msec/div). B, Moderate density of fibrillation potentials (100 V/div; 10 msec/div). C, Severe 
fibrillation potentials (100 V/div; 10 msec/div). (Modified by Cuddon, 2002) 
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Figura 3 Additional abnormal spontaneous electrical activity observed during EMG evalua- tion: 
A, Positive sharp waves (100 V/div; 10 msec/div). B, Complex repetitive discharges (50 V/div; 0 
msec/div). C, Complex repetitive discharges (200 V/div; 10 msec/div).  (Modified by Cuddon, 
2002) 
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MUSCLE BIOPSY 
Biopsies of muscle, and in some cases peripheral nerve, should be collected early 
in the course of diagnostic evaluation of an animal with a neuromuscular disease, 
rather than waiting until extensive muscle damage, fiber loss, and fibrosis have 
occurred, when the chances for a successful treatment are diminished. Delay in 
diagnosis and initiation of appropriate therapy may result in irreversible fibrosis 
and limb contractures (Shelton 2010). 
Muscle biopsies should be collected by an open surgical procedure allowing 
visualization of the orientation of muscle fibers. Evaluation of muscle biopsy 
specimens often offers the most specific information required to make a 
diagnosis. In cases with diffuse involvement, it is better to biopsy easily 
accessible muscles such as the vastus lateralis or biceps femoris muscles. 
Obviously, in animals with focal myopathies, the involved muscles must be 
biopsied. Clinicians are strongly advised to contact their reference laboratory 
before performing the biopsy in order to be clearly informed about the precise 
requirements regarding sampling, handling and shipping of the specimen. 
Generally, fresh or flash frozen samples are easiest to analyze if they have been 
prepared and shipped properly. All hystochemical, histological and immune-
hystochemical investigations can be performed on such samples. Fixation in 
formaldehyde does not allow a comprehensive analysis of the samples. Routine 
analysis of muscle samples should include hystochemical stains such as the 
ATPase stain to evaluate the presence and distribution of the different muscle 
fiber types. For feline muscle, the ATPase stain at pH 4.45 allows good 
differentiation between the main fiber types I, IIA, and IIB. The classical stains 
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haematoxylin and eosin (HE) or Gomori trichrome (GT) are used to screen the 
specimen with respect to muscle fiber size variations, presence of central 
myonuclei, fiber degeneration and necrosis, regenerative attempts, or infiltrates 
with inflammatory cells or connective tissue. Specific techniques aimed at 
staining fibrous tissue, fatty infiltrates and other lesions can then be used as 
needed (Gaschen et al. 2004). 
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IMAGING STUDIES 
Magnetic resonance imaging (MRI) can be used to identify areas of active 
inflammation seen as high-signal intensity areas on fluid-sensitive sequences, and 
minimal atrophy. Using imaging to target the regions of concern could improve 
the efficacy and cost-effectiveness of biopsy. Moreover, MRI is useful to define 
some patterns of muscle atrophy, which can help in the diagnosis of other 
myopathies such as muscle dystrophies (Milisenda et al. 2014). 
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INFLAMMATORY MYOPATHIES 
Myopathies may be classified as inflammatory or noninflammatory. Inflammatory 
myopathies (IMs) include generalized diseases, such as polymyositis and 
dermatomyositis, and focal IMs, such as extraocular and masticatory muscle 
myositis. (Shelton 2006)  
The inflammatory myopathies are infectious or immune mediated. Infectious 
myositis has been reported in association with protozoal organisms 
(toxoplasmosis, neosporosis, hepatozoonosis), bacterial infections (leptospirosis), 
and migrating parasites. (Taylor 2000)  
Myositis is inflammation of muscle, when several muscles are affected, the term 
polymiositis is used to describe the condition. The signs are muscle weakness, 
with muscle swelling and pain during the acute stages and muscle atrophy during 
the chronic stages. Because the inflammation often affects the muscle cell 
membrane, muscle intracellular enzyme may leak out and cause serum activity 
measurements to be higher than normal. Myositis may be of infectious or 
noninfectious origin. Infectious causes may be bacterial, often Leptospira spp. and 
clostridia spp., but also parasitic, such as Toxoplasma spp. and Trichinella spp. 
Non infectious causes of myositis in small animals are probably immunomediated 
conditions. (Amann 1987).  
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INFLAMMATORY MYOSITIS 
- MASTICATORY MYOSITIS: 
Masticatory muscle myositis (MMM) is an inflammatory disorder selectively 
involving the muscle of mastication (temporalis, masseter, medial and lateral 
pterygoid, and rostral portions of the digastricus muscle) in the dog. 
(Amann1987; Shelton 2007, Taylor 2000) 
Two separate disorders were described initially (eosinophilic myositis and 
atrophic myositis), but it is probable that the two are different phases of a single 
disease process. (Taylor 2000)  
Although these names suggest a different pathogenesis, they likely represent the 
acute and chronic phases of masticatory muscle myositis. The acute phase is 
characterized clinically by jaw pain, trismus, and swelling, and the chronic phase 
is characterized by marked muscle atrophy. Without early recognition and 
aggressive treatment, myofiber loss and muscle fibrosis may result in irreversible 
jaw dysfunction and severe muscle atrophy. (Melmed et al. 2004) 
This is an autoimmune disease in which B-lymphocyte-mediated antibodies are 
directed against type 2 M fibers in masticatory muscles. Type 2 M fibers are the 
dominant fiber type in masticatory muscles that are not present in limb muscles 
(Braund 2003). In dogs with MMM, necrosis and phagocytosis are limited to 
these fibers, and there is circulating IgG directed against the unique myosin 
component of these fibers. (Taylor 2000) 
It remains unknown what initiates formation of autoantibodies or why they are 
directed specifically against type 2M fibers. Some theories suggest that molecular 
mimicry may play a role, with antibodies or T cells generated in response to an 
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infectious agent that subsequently cross reacts with self antigens. In this scenario, 
bacterial antigens would have a similar peptide sequence or conformational 
structure to some component of the 2M myofibers. Antibodies directed against 
these bacterial antigens could potentially cross-react with these myofibers. 
(Melmed et al. 2004) 
The classical clinical presentation for masticatory muscle myositis is inability to 
open the jaw (trismus), jaw pain, and swelling or atrophy of the muscles of 
mastication. The average age of onset for masticatory muscle myositis is 3 years 
of age, although patients have reportedly been as young as 4 months of age. The 
disease can occur in any breed, but there may be a predilection for large-breed 
dogs, with overrepresented breeds including German shepherds, Labrador 
retrievers, Doberman pinschers, and golden retrievers. Cavalier King Charles 
spaniels appear to have a genetic predisposition to masticatory muscle myositis. 
No gender predilection has been found.  
In acute form of MMM, there is recurrent painful swelling of the muscle of 
mastication. Exophthalmos and prolapsed of the third eyelid may occur, caused by 
pressure on retrobulbar tissues from swollen musculature. Rarely enough 
stretching or compression of the optic nerve occurs to cause blindness. Pyrexia, 
submandibular and prescapular lymphadenopathy, and tonsillitis are variably 
present during recurrent symptomatic episodes, which may last 1 to 3 weeks. 
Affected dogs are reluctant to eat during episodes and may salivate profusely. 
Palpations of the muscles of the head and attempts to open the mouth are met with 
resistance because of pain. (Braund 2003, Melmed et al. 2004, Podell 2002, 
Taylor 2000) 
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Unfortunately, most owners do not recognize a problem until the chronic phase, 
which is characterized by marked muscle atrophy with or without persistent 
trismus. Enophthalmos may be present in the chronic phase because of atrophied 
pterygoid muscles. (Melmed et al. 2004) 
Chronic MMM is more commonly recognized than the acute form. Affected dogs 
are bright, alert, and systemically normal, but there is progressive severe atrophy 
of the temporalis and masseter muscles, resulting in a skull-like appearance of the 
head. Dogs with chronic MMM may have difficulty in opening their mouths wide 
enough to eat; in some cases, the jaw cannot be opened even under general 
anesthesia. (Taylor 2000) 
The diagnosis of MMM is suspected based on clinical findings. Initial diagnostic 
testing should include a complete blood count and serum chemistry profile, 
including a creatine kinase (CK) level. Biochemical changes that have been 
documented in patients with masticatory muscle myositis include 
hyperglobulinemia, mild anemia, and proteinuria. Although peripheral 
eosinophilia has been reported, it has not been a consistent clinicopathologic 
finding. CK levels are frequently elevated during the acute phase, but are often 
normal as the disease becomes more chronic. The degree of enzyme elevation, if 
present, is relatively less than that in patients with polymyositis, because of the 
smaller muscle mass affected.  
A confirmatory blood test for circulating antibodies against masticatory muscle is 
critical to confirm the diagnosis. Clinical signs compatible with masticatory 
muscle myositis and positive results from a 2M antibody test confirm the 
diagnosis. However, false negatives may occur if immunosuppressive dosages of 
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corticosteroids have been administered for 7 to 10 days before testing and in end-
stage masticatory muscle myositis with loss of myofibers and fibrosis. (Melmed at 
al. 2004, Podell 2002, Taylor 2000) 
Other procedures that may aid in diagnosing masticatory muscle myositis include 
radiology and advanced imaging, electrodiagnostics, and histologic evaluation of 
biopsy specimens. (Melmed et al. 2004) 
Electromyography (EMG) may be a useful diagnostic procedure, particularly in 
differentiating masticatory muscle myositis from polymyositis. 
Electromyographic abnormalities seen with myopathic disease include increased 
insertional activity, fibrillation potentials, positive sharp waves, and complex 
repetitive discharges. Abnormalities may be severe during the acute phase of the 
disease. However, EMG results may be normal in patients with end-stage disease 
because of severe atrophy or loss of muscle fibers and fibrosis. In these patients, 
the only change evident may be decreased insertional activity due to loss of 
muscle fibers.  
Evaluating a muscle biopsy can also provide diagnostic confirmation of the 
disease as well as additional information regarding prognosis, particularly when 
muscle atrophy is present and significant fibrosis is suspected. Muscle biopsy 
documents the severity of fiber loss and degree of fibrosis, which are important in 
determining the long-term prognosis and probable success of therapy. Muscle 
biopsy is a simple surgical procedure. Biopsies are typically obtained from the 
temporalis muscle; however, care must be taken to avoid sampling the frontalis 
muscle, which overlies the temporalis muscle, because it is not affected in 
masticatory muscle myositis. In addition, biopsies are important for prognosis and 
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determining the usefulness of immunosuppression. If only fibrosis is present 
without remaining myofibers or inflammation, the rationale for using 
immunosuppression should be questioned. (Melmed at al. 2004, Taylor 2000) 
A favorable outcome in masticatory muscle myositis necessitates early accurate 
diagnosis and appropriate therapy. Treatment is centered on aggressive 
immunosuppression, which is generally achieved by corticosteroid administration. 
The cornerstone of therapy is prednisone at 2 mg/kg PO bid during the acute 
phase. This dose should be maintained until maximum jaw function has been 
regained and CK levels have returned to normal. At that time, prednisone can be 
slowly tapered to the lowest every-other-day dose that abates clinical signs. This 
process should generally occur slowly over 4 to 6 months. Although low-dose 
alternate-day therapy is generally well tolerated, long-term prednisone may result 
in iatrogenic hyperadrenocorticism and susceptibility to infections. Owners should 
be prepared for resultant polyuria, polydipsia, and polyphagia associated with 
prednisone administration as well as the potential for steroid-induced gastric 
ulcers. In addition, corticosteroid therapy alone can result in masticatory muscle 
atrophy. If the side effects of prednisone therapy cannot be tolerated, alternative 
immunosuppressive agents may be used. Azathioprine is another 
immunosuppressive drug that can be considered in addition to traditional 
corticosteroid therapy. Although azathioprine is generally not included in the 
initial therapy for masticatory muscle myositis, it can be used in conjunction with 
prednisone in patients that are unable to tolerate the side effects of corticosteroids 
or are refractory to prednisone therapy alone. Azathioprine should be dosed at 2 
mg/kg PO q24–48h and continued over several months while prednisone is slowly 
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tapered to a maintenance dose. Side effects associated with azathioprine include 
bone marrow suppression and hepatotoxicity. If untreated or treated 
inappropriately, the acute phase will progress to the chronic phase. A common 
problem in treating masticatory muscle myositis is using an inadequate dose of 
corticosteroids for too short a time. It is common for masticatory muscle myositis 
to respond initially to therapy, but relapses usually occur quickly if treatment is 
discontinued prematurely. The chronic phase is marked by severe muscle atrophy 
resulting from gradual replacement of muscle fibers with fibrous tissue. 
Corticosteroids may prove helpful in the chronic phase, although lower doses are 
recommended. The clinical application of corticosteroids in the chronic phase is 
based on the belief that therapy may reduce further fibrosis. Patients experiencing 
significant trismus may require gruel diets to maintain adequate nutritional intake. 
Patients can also be encouraged to chew toys or bones to promote use of their 
masticatory muscles. The literature has historically recommended forcible 
opening of the jaw while patients are under anesthesia. But nowadays retraction of 
the jaw is strictly contraindicated. The prognosis is determined by the degree of 
fibrosis present and the clinical response to immunosuppression. Aggressive 
treatment during the acute phase generally results in a good prognosis. It is 
important to remember that corticosteroids alone can cause muscle atrophy and, 
therefore, progressive atrophy may not be indicative of worsening disease. 
Treatment failure and relapses usually result from inadequate immunosuppression 
and hasty discontinuation of corticosteroids. Patients treated in the chronic phase 
of the disease carry a more uncertain prognosis but can do well if extensive 
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fibrosis does not result in persistent jaw dysfunction. (Melmed at al. 2004, Podell 
2002, Taylor 2000) 
 
- EXTRAOCULAR MUSCLE MYOSITIS 
Extraocular polymyositis (EOM) is a relatively uncommon condition of dogs, of 
which there are limited reports in veterinary literature. (Mitchell 2008) EOM is a 
focal inflammatory myopathy of dogs localized to the extraocular muscles. 
Masticatory and limb muscles are normal, suggesting that myofiber-specific 
antigens unique to the extraocular muscles may play role in their selective 
immune-mediated destruction. (Taylor 2000) 
This disorder has been reported primarily in young dogs aged 6 to 24 months. 
Large-breed dogs, particularly Golden Retrievers, are most commonly affected, 
and females are most frequently affected. (Taylor 2000, Mitchell 2008) Acute 
bilateral exophtalmos is the most dramatic finding. (Taylor 2000) EOM can cause 
exophthalmos and strabismus due to inflammation of the extraocular muscles. 
EOM is typically non-painful, and protrusion of the third eyelid is not a feature. 
(Mitchell 2008) Serum CK is normal or mildly increased. Orbital sonography 
reveals swollen extraocular muscles and rules out a retrobulbar mass or abscess. 
The extraocular muscles are smaller and difficult to biopsy due to their location.  
Muscle lesions are confined to these muscles: in typical muscle sections affected 
with EOM, histopathology shows myonecrosis with mononuclear infiltrate of 
CD3+ T-lymphocytes and occasional macrophages in extraocular muscle bellies. 
The inflammatory nature of the affected extraocular muscles and excellent 
responsiveness to steroids suggests an immune-mediated basis for the myositis. 
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Swelling of the extraocular muscles restricts globe movement resulting in 
strabismus. (Mitchell 2008)  
Treatment consist in using immunosuppressive dose of corticosteroids, which can 
be gradually tapered after three weeks, depending upon response. Azathioprine 
can be used when the corticosteroids are contraindicated or unsuitable for the 
patient. Early treatment carries a good prognosis and there may be no permanent 
effects. Prolonged swelling of affected muscles may result in fibrosis leading to 
enophthalmos and pronounced strabismus which could hinder vision. (Taylor 
2000, Mitchell 2008) 
 
- IDIOPATHIC POLYMYOSITIS 
In human polymyositis (PM) is classified as a separate entity among idiopathic 
inflammatory myopathies, but it is considered as the least common since it is an 
exclusion diagnosis. It is believed that physical, chemical or external infectious 
agents act upon a genetically predisposed person. The relationship of PM with 
other autoimmune disorders, the existence of autoantibodies, histocompatibility 
genes, the presence of T cells in muscle tissue and their response to 
immunotherapies have led PM to be considered an autoimmune disease, but no 
specific target antigens have been identified yet. (Milisenda et al. 2013) 
Idiopathic polymyositis is an inflammatory myopathy in the dog and cat not 
associated with any other systemic connective tissue disease or infectious cause. 
The condition can either affect focal muscle groups (extraocular, laryngeal) or 
manifest as multifocal or diffuse involvement of skeletal muscle. (Podell 2002) 
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In the dog, there seems to be a predilection for larger breed and mature to older 
dogs, although any age or breed of dog may be affected. Large-breed adult dogs 
are most commonly affected, with many reported cases in German Shepherds. 
There may be a slight gender predilection for female dogs. (Taylor 2000) 
The clinical signs are variable and may wax and wane initially. Progressive 
exercise intolerance with acute exacerbation of weakness may occur. The gait is 
often characterized by a profound stiffness, with dogs looking as if they are 
gingerly tip-toeing with extremely short steps (‘‘walking on eggshells’’). Cervical 
ventroflexion and a lordotic posture can be seen. (Podell 2002) 
Muscle palpation elicits obvious pain in some dogs with PM, although non-
painful muscle atrophy occurs in others. Regurgitation caused by megaesophagus, 
dysphagia, excessive salivation, pyrexia, and a weak bark are occasionally 
recognized. Signs may be intermittent. (Taylor 2000) 
The criteria for a definitive diagnosis of idiopathic polymyositis are not well 
defined in veterinary medicine. Podell diagnoses idiopathic polymyositis by 
confirming three or more of the following: (1) clinical signs (as described), (2) 
elevation of CK, (3) abnormal EMG with a normal motor nerve conduction study, 
(4) negative autoimmune and infectious disease antibody titers, and (5) 
inflammatory muscle biopsy. 
Thoracic radiographs are recommended to evaluate for the presence of 
megaesophagus even if it is not clinically evident. Whenever possible, EMG 
should be performed to document that abnormalities are present in multiple 
muscle and to identify the most dramatically involved muscle groups prior to 
biopsy. When a severely affected muscle is located, it is recommended that a 
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biopsy be taken of that same muscle group on the opposite side of the dog to 
avoid artifacts caused by the EMG needle. EMG changes can include prolonged 
insertional activity, positive sharp waves, fibrillation potentials, and bizarre high-
frequency discharges. (Taylor 2000) 
If EMG is not available, the most painful muscles should be biopsied before the 
onset of any therapy. Typical changes in the muscle include a mononuclear 
inflammatory infiltrate with or without eosinophils that is often perivascular, 
invasion of non-necrotic fibers by cellular infiltrates, and myofiber necrosis. 
(Podell 2002) 
Therapy is focused on immunosuppression, initial pain relief, and supportive care. 
Prednisone at 2 mg/kg administered orally twice daily is the recommended initial 
therapy. Care must be taken if aspiration pneumonia is present when instituting 
immunosuppressive therapy. It is advisable to begin systemic appropriate 
bactericidal antibiotics for 24 hours before the onset of corticosteroid therapy in 
the face of aspiration pneumonia. Prednisone can then be gradually increased over 
several days while the animal is monitored closely. A fentanyl patch is 
recommended for pain relief for the first 72 hours. Appropriate changes in feeding 
should be implemented if megaesophagus is present. The prognosis for idiopathic 
polymyositis is generally good in dogs and cats without megaesophagus. Long-
term, and sometimes lifelong, corticosteroid therapy may be needed to prevent 
clinical relapse. Alternative immunosuppressive therapy may be helpful to reduce 
the reliance on higher doses of corticosteroids. (Podell 2002) Whenever the 
diagnosis of an inflammatory myopathy is made, every attempt should be made to 
rule out an infectious cause. Serum titers should be measured against Toxoplasma 
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gondii, Neospora caninum, and tick-related diseases when appropriate. Clinical 
signs of infectious polymyositis may be present as early as 4 weeks of age and 
include progressive paraparesis and "bunny hopping" gait with progression to 
pelvic limb hyperextension and muscle atrophy. Progression to pelvic limb 
hyperextension is more likely when infection develops prior to 4 months of age. 
Serum CK concentration is usually elevated. Elevated concentrations of serum 
and CSF antibodies against N. caninum and T. gondii support the presence of 
infection. Occasionally organisms are found within muscle biopsy sections. 
Treatments have included clindamycin and sulfadiazine and trimethoprim. While 
some improvement may be noted in neurological function, complete resolution of 
pelvic limb hyperextension has not been reported to occur. (Shelton 1999) 
 
- FAMILIAL CANINE DERMATOMYOSITIS 
Dermatomyositis (DM) or familial canine dermatomyositis is a well documented 
disease of Collie dogs, of all coat colors and both coat lengths. Dermatomyositis 
has also been reported in the Shetland Sheepdog (Shelty), Beauceron Shepherd, 
Pembroke Welsh Corgi, Australian Cattle dog, Lakeland Terrier, Chow Chow, 
German Shepherd, and Kuvasz. (Braund 2003) Male and female can be affected. 
DM is an inflammatory disease of striated muscle, skin, and vasculature; in 
humans, adult and juvenile forms have been described. Perivascular 
accumulations of inflammatory cells are early changes. Angiopathy is 
characteristic of this disease, particularly in the childhood form, and a 
perifascicular pattern of muscle fiber atrophy is characteristic. In dogs, the skin 
lesions are most problematic, and the muscle lesions usually mild. In contrast, in 
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humans, the muscle lesions are the most problematic. While the condition are not 
identical, vascular lesions are present in both conditions. (Shelton 2007) 
An autoimmune pathogenesis with immune complex deposition is suspected, 
although the definitive target antigens are not identified. According to Podell 
(2002) the onset of clinical signs is typically within the first 6 months of life, 
instead according to Braund (2003) the onset is within 2 and 6 months of age, and 
yet according to Grossa and Kunkle (1987) the onset is usually between the 12 to 
14 weeks. 
Cutaneous lesions develop mainly on the face and ears, although the tail tip and 
bony prominence areas may be affected. The initial signs are development of 
cutaneous vesicles when the dog is between 2 and 4 months of age, followed by 
erythema, ulceration, alopecia, crusting, and changes in pigmentation. Less 
commonly, adult dogs may develop more severe dermatologic signs later in life, 
which may be precipitated by stress events such as trauma, parturition, or even 
prolonged sunlight exposure. The myositic signs develop typically after the 
dermatitis and correlate in severity approximate to the degree of dermatitis. The 
temporalis muscle is the initial and most commonly affected muscle group. 
Difficulty in prehending food, dysphagia, and temporalis muscle atrophy are 
classic signs. More severe signs include megaesophagus with regurgitation and 
generalized polymyositis, leading to diffuse muscle atrophy over time. Unlike 
idiopathic polymyositis, DM lesions are more prevalent in temporalis and distal 
appendicular muscles. (Podell 2002) 
The cutaneous lesions consist of pustules, ulcers, and vesicles which may progress 
rapidly to crusted or alopecic areas. Myositis develops several months later and 
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principally involves muscles of mastication and muscles of the extremities below 
the elbow and stifle. The muscle lesions appear to correlated with the severity of 
the skin lesions. Muscle lesions consist of multifocal muscle fiber necrosis, 
internalization of muscle nuclei, atrophy, fibrosis, and regeneration, and mild to 
severe interstitial and perivascular inflammatory cell infiltrates (lymphocytes, 
neutrophils, plasma cells, and macrophages). Small intrafascicular nerves may be 
surrounded by inflammatory cells. Vasculitis is seen in skin, muscle, and 
occasionally in other tissues. Necrotizing vasculitis of small venules and arterioles 
is characterized by fibrinoid thickening of the vessel wall, pyknosis and 
karyorhexis of endothelial cell nuclei, and neutrophilic inflammation. In many 
cases, the lesions spontaneously regress by 6 to 8 months of age, although 
severely affected dogs may have dermatitis throughout their lives. Differential 
diagnosis of the skin lesions includes demodicosis, dermatophytosis, 
staphylococcal folliculitis, epidermolysis bullosa simplex, and discoid lupus 
erythematosus. There is a dramatic increase in serum concentrations of IgG and 
circulating immune complexes, which may be detected before clinical signs and 
which show a positive correlation with disease severity, and which decline as 
animals enter remission. Non-regenerative anemia due to chronic inflammation 
may occur in severely affected dogs. CK level are usually normal, but may be 
increased. The presence of fibrillation potentials, positive sharp waves, and 
bizarre high frequency discharges has been demonstrated electromyographically. 
(Braund 2003) 
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The diagnosis of dermatomyositis includes a combination of factors. Five criteria 
have been used to define human dermatomyositis. These include: 
1) Symmetrical skeletal muscle weakness 
2) Muscle biopsy evidence of myositis 
3) Elevation of serum skeletal muscle enzymes 
4) Characteristic electromyographic changes 
5) Dermatologic features consisting of erythematous areas over knuckles, elbows, 
knees, medial malleoli, face, neck, and upper torso 
According to Halgis et al. (1984) the dogs had similar features, including 
1) Symmetrical muscle atrophy 
2) Muscle biopsy evidence of multifocal myositis 
3) Electromyographic changes suggestive of a myopathy 
4) Dermatologic features of erythema and inflammation of periorbital, facial, and 
lip skin, and skin surfaces subject to trauma such as elbows, stifles, carpi, tarsi, 
feet, and sternum. 
Therapy revolves around symptomatic relief of skin lesions and 
immunosuppression with prednisolone, at 1 to 2 mg/kg PO bid. Prolonged or 
recurrent steroid therapy may be necessary. Additional recommended therapy 
includes avoidance of sunlight, neutering for female dogs, treatment of underlying 
pyoderma, and vitamin E. Pentoxifylline, a methylxanthine that increases 
microvascular blood flow, may have some benefit for treatment of familial canine 
DM. The overall prognosis for less severely affected dogs is usually good. (Podell 
2002; Braund 2003)  
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MUSCULAR DYSTROPHIES 
Muscular dystrophies (MD) are a heterogeneous group of inherited, degenerative, 
mostly non-inflammatory disorders characterized by progressive muscle weakness 
and wasting. Until recently, one form of muscular dystrophy was recognized in 
dogs and cats (the X-linked dystrophin deficiency). More recently, however, 
merosin (laminin α2) deficiency and other apparently autosomal forms of 
muscular dystrophy have been detected. (Shelton & Engvall 2002) A better 
understanding of the pathogenesis and clinical features of this class of myopathy 
allows nowadays a progressive enrichment of the literature and the description 
and molecular characterization of different dystrophies, partially or totally 
correspondent to analogues human diseases. (McGreevy et al. 2015, Munday et al. 
2014; Baroncelli et al. 2014; Atencia-Fernandez S. et al. 2014)  
A precise classification of dystrophic muscle disorders is critical since some of the 
disorders are the result of X-linked inheritance, whereas others are inherited in an 
autosomal recessive or dominant fashion. An accurate classification is important 
to animal breeders and owners, because diagnosis, disease progression, prognosis, 
and patterns of inheritance differ for the various forms of MD. Some forms of MD 
are severe and lethal relatively early, while other forms are slowly progressive and 
the animal may stabilize and live a near-normal life, although activity may be 
limited. (Zucconi E. et al. 2010; Zatz M. et al. 2015) Because of the large number 
of possible forms of MD, the variable clinical presentations for each one, and the 
overlap between different forms, it is difficult to classify the disease based solely 
on clinical signs such as age of onset or pattern of muscle involvement. 
Furthermore, because limited information is available on MD in dogs and cats 
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other than for dystrophin deficiency, it is difficult to extrapolate the clinical 
picture from what is known in the human diseases. A dystrophic myopathy should 
be considered in any young dog or cat (male or female, mixed breed or purebred) 
with persistent muscle weakness, muscle atrophy or hypertrophy, gait 
abnormality, or contractures beginning in the first few months of life. Dysphagia, 
regurgitation, and dyspnoea may occur as a result of hypertrophy of the lingual, 
pharyngeal, and oesophageal musculature and the diaphragm. Specific therapies 
are not currently available and the general prognosis is poor. (Shelton 2004) 
The most common form of muscular dystrophy in human beings, Duchenne 
muscular dystrophy (DMD), was shown in 1987 to be caused by a lack of the 
muscle-associated protein called dystrophin. A mild form of DMD is often 
referred to as Becker muscular dystrophy (BMD). Dystrophin is not absent in 
BMD but is mutated and structurally altered and only partially functional. Several 
other skeletal muscle proteins have since been identified as involved in other X-
linked and autosomal forms of muscular dystrophy. Several of these proteins are 
directly or indirectly linked to dystrophin. (Shelton & Engvall 2002) 
The two most common forms of muscular dystrophy are severe and relatively 
early lethal. Because of the large number of forms of muscular dystrophy, the 
variable clinical presentations for each one, and the overlap between different 
forms, it is difficult to classify disease solely on clinical signs such as age of onset 
or pattern of muscle involvement. (Shelton et Engavall 2002) 
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►Muscular Dystrophy in Dogs and Cats with Absence of Dystrophin 
DMD associated with an absence of dystrophin and genetic mutations of the 
dystrophin gene is the most common and best studied of the muscular dystrophies 
in human beings and companion animals. (Shelton & Engvall 2002) Dystrophin is 
a 400-kilodalton protein that functions to stabilize the muscle membrane during 
contraction.(Bergman R.L. et al 2002) The dystrophin gene is located on the X-
chromosome; thus, DMD is an X-linked recessive trait transmitted by a female 
carrier, who is most often asymptomatic and only rarely manifests clinical signs 
of limb weakness and myopathic changes on electromyography and muscle 
biopsy. Similar to DMD in human beings, all reported dogs with canine X-linked 
muscular dystrophy (CXMD) and cats with feline X-linked muscular dystrophy 
(FXMD) have been male. (Shelton & Engvall 2002) CXMD was first described in 
the Golden Retriever. (Bergman R.L. et al 2002). Muscular dystrophy with 
dystrophin deficiency has been documented afterwards in several breeds of dogs.  
The clinical phenotype of reported dystrophin deficiencies differs between dogs 
and cats. An absence of dystrophin has been associated in dogs with generally 
diffuse muscle atrophy, except for specific muscles that hypertrophy (i.e., 
semimembranosus, semitendinosus, and tongue muscles); on the contrary it is 
associated with generalized muscle hypertrophy in cats. A peculiarity of FXMD is 
the presence of calcified nodules on the tongue in addition to tongue hypertrophy. 
The serum creatine kinase (CK) concentration is usually markedly elevated in 
dogs and cats with dystrophin deficiency; normal or only mild elevations may be 
found in manifest female animals. Typical pathologic changes of the dystrophic 
muscle include myofiber degeneration, regeneration, fibrosis, and calcific 
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deposits. The diagnosis of a dystrophic myopathy can be confirmed in most 
instances by the histopathologic evaluation of properly processed muscle biopsy 
specimens. Absence of dystrophin in immunohistologic analysis provides 
conclusive diagnosis. Electrophysiological abnormalities have been described, 
including complex repetitive discharges, positive sharp waves, and fibrillation 
potentials. These EMG changes tend to increase until 4 months of age. (Bergman 
et al. 2002) 
Specific therapies are not currently available for CXMD or FXMD, and the 
general prognosis is poor. (Shelton et Engvall 2002) 
 
► Muscular Dystrophy with Merosin (Laminin α2) Deficiency 
Congenital muscular dystrophies (CMDs) in human beings are a heterogeneous 
group of autosomal recessive diseases manifest at birth or during infancy with 
muscle atrophy, hypotonia, weakness, and contractures. Approximately 50% of 
human CMD patients have a deficiency of merosin (laminin α2) expression in 
muscle. Laminin α2 is the major component of the basal lamina that surrounds 
each muscle fiber. Laminin α2 is one of the extracellular ligands for the 
dystrophin-associated glycoprotein complex; it links dystrophin to the 
extracellular matrix and contributes to the stability of the muscle basement 
membrane. (Shelton & Engvall 2002). Laminin α2 related CMD is caused by 
mutations in the LAMA2 gene, encoding the α2 heavy chain of the laminin 211 
isoform (α2/β1/γ1), also known as merosin. In the genetic nomenclature, this 
CMD subtype is also referred to as MDC1A. Complete absence of laminin α2 
staining on muscle (or skin biopsy) is more common and in general associated 
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with a more severe non-ambulatory phenotype compared to a partial laminin α2 
deficiency. (Bönnemann et al. 2014) Laminin α2 is also found in the basement 
membrane of Schwann cells and in blood vessels within the brain as well as in 
other tissues. Most of the cases of laminin α2-deficient CMD are associated with 
mutations in the laminin α2 gene (LAMA2). Peripheral nervous system 
involvement in primary laminin α2 deficiency is suggested by reduced motor 
nerve conduction velocity. (O’Brien et al. 2001). O’Brien et al. (2001) described 
this pathology in two female cats, the cats have shown an elevate value of creatine 
kinase (CK). Histopathologically they found dystrophic changes were present in 
all skeletal muscles examined. Endomysial fibrosis was marked in both cats. In 
addition, muscles from both cats showed myofiber necrosis, variability of fiber 
size and perimysial lipid accumulation. 
Laminin α2-deficient CMD was also described in two Great Dane dogs referred 
for quadriceps femoris contracture. The pathological features described in muscle 
biopsies are simila to primary merosin deficiency in humans (Trapani F. et al. 
2010). 
The histologic phenotype of a dystrophic myopathy was determined by evaluation 
of muscle biopsy specimens, and the exact classification of the muscular 
dystrophy was confirmed by immunohistochemical analysis. Laminin α2 is also 
found in Schwann cell basement membrane and is thought to play a role in 
ensheathment and myelination of the peripheral nerve. for the dystrophin-deficient 
muscular dystrophies, no specific therapy is available for laminin α2 deficiency, 
and the prognosis is poor. (Shelton et Engvall 2002). And also for the diagnosis in 
human Sewry et al.(1996) state that human skin expresses the α2 chain of laminin, 
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and this tissue can be used to identify patients with congenital muscular dystrophy 
with a deficiency of the α2 chain. Muscle biopsy specimens from both cases 
showed a deficiency of laminin α2, similar to that observed in other merosin-
deficient cases. The deficiency of the α2 chain in the skin therefore confirmed the 
results obtained from the muscle samples. 
MD associated with complete or partial loss of dystrophin and dystrophin-
associated proteins or laminin α2 deficiency has been documented in female 
purebred and mixed-breed dogs. Although muscular dystrophy in dogs has 
generally been thought of as a disease affecting only young purebred males. 
(Shelton et al. 2001) 
► Hereditary Myopathy of Labrador Retrievers 
An inherited myopathy affecting male and female yellow and black Labrador 
Retrievers less than 6 months of age was first described in 1976. Affected dogs 
had reduced muscle mass with a poor conformation, a stiff ‘‘bunny hopping’’ gait, 
and abnormal head and neck posture. Clinical signs were exaggerated with 
exercise, exposure to cold temperatures, or excitement but did not worsen with 
age but rather stabilized at about 1 year of age. Evaluation of muscle biopsy 
specimens revealed a predominance of type 1 fibers with a paucity of type 2 
fibers; hence, the description of this disorder as a type 2 fiber deficiency. Further 
studies documented the inheritance pattern as autosomal recessive in nature. 
As a result of the diverse pathologic changes that may be present in muscle biopsy 
specimens from dogs with a similar clinical presentation, including myopathic and 
neuropathic abnormalities, the hereditary myopathy of Labrador Retrievers 
(HMLR) disorder has been variably referred to as muscular dystrophy, myotonia, 
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polyneuropathy, and hereditary myopathy. Immunohistochemical studies using 
established monoclonal and polyclonal antibodies against dystrophin, dystrophin 
associated proteins, and laminins have failed to identify any of the previously 
described protein deficiencies associated with human or canine muscular 
dystrophy as the basis for this disorder. The presence of angular atrophied fibers 
of both muscle fiber types and a type 1 fiber predominance observed in many of 
the affected dogs is, however, highly suggestive of neuropathy, although 
pathologic abnormalities of peripheral nerve or spinal cord have not yet been 
identified. (Shelton et Engvall 2002) 
HMLR is not the only muscle disease affecting Labrador Retrievers. The recent 
identification of dystrophin-deficient muscular dystrophy in a young male 
Labrador Retriever emphasizes the importance of a correct diagnosis and 
classification of the muscle disorder, as the mode of inheritance and prognosis 
differ between HMLR and CXMD. Dogs with HMLR tend to stabilize in clinical 
severity by 1 year of age and may be acceptable pets, although exercise capacity is 
limited. This is in contrast to the poor prognosis of CXMD. Similar to the 
previously described muscular dystrophies, no specific therapies are available for 
HMLR. Housing in a warm area has been advised, however, because exposure to 
cold may exacerbate the condition. Moreover, as muscle carnitine concentrations 
have been low in a few dogs tested with HMLR, supplementation with L-carnitine 
(50 mg/kg administered orally twice daily) may be of benefit in improving muscle 
strength. Because a test for carriers is not available, breeders should be advised 
not to breed parents or siblings of affected dogs. (Shelton & Engvall 2002) 
 57 
Recently, muscular disrophy resembling human Becker muscular dystrophy was 
described in a dog (Baroncelli et al., 2014).  Furthermore a sarcolemmal specific 
collagen VI deficient myopathy was reported in a Labrador Retriever (Marioni-
Henry et al., 2014) and a mutation in the PTPLA gene was correlated to the 
Centronuclear myopathy in the same breed. (Maurer et al, 2012) It may be that 
immunoistochemical molecular studies will allow a better understanding and a 
precise characterization of several CMD and FMD. 
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METABOLIC MYOPATHIES 
Many endocrinologic disorders, endogenous and iatrogenic, result in muscle and 
likely peripheral nerve disease. Endocrine myopathies are a relatively common 
occurrence in geriatric animals and may present with a variety of clinical 
syndromes ranging from mild weakness or stiffness to complete collapse. (Platt 
S.R. 2002) 
Myopathy secondary to glucocorticoid excess occurs in Cushing’s disease and as 
a result of chronic exogenous corticosteroid therapy (iatrogenic steroid 
myopathy). (Platt S.R. 2002) Apart from the development of a pendulous 
abdomen, decreased muscle mass may be noted around the limbs, over the spine 
or over the temporal region. Muscle weakness is the result of muscle wasting 
caused by protein catabolism. Occasionally, dogs with hyperadrenocorticism 
develop myotonia, characterized by persistent active muscle contractions that 
continue after voluntary or involuntary stimuli. All limbs may be affected but the 
signs are usually more severe in the hindlimbs. Animals with myotonia walk with 
a stiff stilted gait. The affected limbs are rigid and rapidly return to extension after 
being passively flexed. In some cases passive flexion may be difficult or 
impossible to achieve because of the persistent muscle tone. Spinal reflexes are 
difficult to elicit because of the rigidity, but pain sensation is normal. (Herrtage 
M.E. 2004) 
A number of mechanisms have been proposed to explain how corticosteroids 
(exogenous or endogenous) produce muscle weakness and wasting. 
Glucocorticoids are highly lipid-soluble and easily partition through the cell 
membrane into the cytosol. Inside the cell, these hormones bind to specific 
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cytoplasmic receptors which act by modifying transcription. The major actions of 
glucocorticoids are to increase muscle protein catabolism and inhibit synthesis of 
myofibrillar proteins. The weakness and muscle atrophy resulting from 
corticosteroid therapy is not likely a result of motor nerve damage. Motor nerve 
conduction velocity and histologic studies of nerve were normal in corticosteroid-
treated animals. (Platt S.R. 2002) 
The clinical manifestations of Cushing’s myopathy are similar to that of 
exogenous steroid myopathy with muscle atrophy and weakness. Unilateral pelvic 
limb stiffness has been described as a frequent initial sign, with other limbs 
becoming gradually involved over time. Severe pelvic limb rigidity and clinical 
myotonia have been found in a subset of dogs with chronic Cushing’s disease. 
Type 2 fiber atrophy is a consistent abnormality in muscle biopsies from dogs 
affected with Cushing’s myopathy. Deposition of perimysial and endomysial fat 
has been described. (Platt S.R. 2002) 
Muscle weakness occurs frequently in association with hypoadrenocorticism 
(Addison’s disease) in cats and dogs. The weakness is usually generalized and 
may involve the pharyngeal or esophageal musculature. Hypoadrenocorticism 
classically includes mineralocorticoid and glucocorticoid deficiency. Adrenal 
insufficiency impairs muscle carbohydrate metabolism, water and electrolyte 
balance, muscle blood flow, and adrenergic sensitivity, which are all factors that 
contribute to the weakness associated with Addison’s disease. Hyperkalemia 
develops with depletion of muscle intracellular potassium, decreased membrane 
sodium potassium–adenosine triphosphatase activity, and diminished β-adrenergic 
stimulation of the sodium-potassium pump. Correction of the electrolyte 
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imbalance and glucocorticoid deficiency usually corrects the clinical weakness. 
(Platt S.R. 2002) 
In human medicine, myopathy (Mor F. et al. 1987), rhabdomyolysis (Su Yin Lau 
SY and Yong TY, 2012) and fibromyalgia like syndrome (Kaganov Yet al. 2000)  
secondary to Addison’s disease were described.  
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MISCELLANEOUS 
In this chapter a group of disease of uncertain etiology and pathogenesis were 
described. They share some clinical features with myopathies, but histopathology 
have failed until now to achieve a definitive understanding of them.   
 
◊ SWIMMING PUPPY SYNDROME 
Swimming puppy syndrome is an uncommon developmental disorder of the motor 
function, still poorly characterized, seen in dogs and less frequently in cats, at an 
average age of 15 to 21 days after birth. (Cardilli et al. 2013) 
It is also known as swimmer syndrome, flat pup syndrome, splay leg 
(paraparesis), splay weak (tetraparesis), and myofibrillar hypoplasia and is 
described as a musculoskeletal disorders in puppies. (Nganvongpanit & Yano 
2013) 
The etiology of swimmer syndrome is uncertain and difficult to prove. Many 
hypotheses have been suggested, including hereditary factors, environmental 
causes, unbalanced diet (excessive protein in the queen's diet), maternal metabolic 
disorders, musculoskeletal development problems, obesity, and neurological 
disorders. (Cardilli et al. 2013) 
The condition is mostly seen in brachycephalic dog breeds, and an association 
with pectus excavatum has been previously reported. The animals try to ambulate 
with swimmer like movements, and when positioned on smooth surfaces, the 
clinical signs are more pronounced. (Verhoeven et al. 2006; Cardilli et al. 2013) 
In the initial weeks of life, newborn puppies seem normal: they gain weight 
quickly, suck well, and appear to be completely healthy. Signs begin to appear 
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when the puppy learns to walk (2nd-3rd week), with spread out legs like a 
swimmer. In some cases, there are additional complications, because such puppies 
tend to lie on their bellies most of the time. 
The center of gravity is shifted to the chest, while the soft ribs cannot maintain 
their correct shape; thus the chest, under the pressure of body weight, splays on 
both sides, and the thorax becomes flat (funnel chest). Sterna concave, 
dorsoventral flattening of the chest, or pectus excavatum will present when 
forelimbs are affected. In cases of pectus excavatum, puppies show respiratory 
insufficiency, with dyspnoea, mouth continuously open, bluish mucous 
membranes, and medial patellar luxation and malformation of articulations of the 
long bones (genu recurvatum). ( Nganvongpanit & Yano 2013;Cardilli et al. 
2013; Verhoeven et al. 2006) 
The results of a study showed that complete blood counts and the levels of most 
blood chemicals were not useful for diagnosis of swimming puppy syndrome. 
Although serum CK was elevated in animals with swimming puppy syndrome 
compared with control puppies and with normal levels, it cannot be used for 
diagnosis of this disease due to silent elevation. However, CK could be used as a 
tool for prognosis of the disease and to evaluate the efficacy of treatment. 
(Nganvongpanit K. 2012) 
A definitive diagnosis can be made based on history, clinical signs and 
radiographic examination. The differential diagnosis of this disease includes 
encephalomeningitis, canine distemper, toxoplasmosis, neosporosis, myopathies, 
and spina bifida. The treatment success rate is dependent on the time of diagnosis 
and treatment. Usually puppies with this disease recover well after early diagnosis 
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and treatment. Swimmer syndrome treatment should include dietary 
modifications, relocation to rough surface for motor stimulation, anatomical 
immobilization of the affected limbs, physical therapy, thermo and hydrotherapy, 
and massage for muscle strengthening. (Nganvongpanit & Yano 2013; Cardilli et 
al. 2013; Verhoeven et al. 2006) 
 
◊ CARPAL LAXITY SYNDROME 
Congenital deformities are multifactorial (teratogenic agents, intra-uterine mal-
positioning,diseases of the mother during pregnancy etc). Acquired deformities 
can occur due to trauma, infectious polyarthritis and nutrition. Vaughan (1992) 
has suggested that Doberman Pinschers may be predisposed to carpal flexural 
deformity, and that this lesion may be hereditary. Altunatmaz & Ozsoy due to the 
cases in their study belonging to different breeds, and lack a dominant breed, do 
not agree with the idea postulated by Vaughan. 
The carpal laxity syndrome is defined as carpal hyperflexion or hyperextension of 
the carpal joints. Hyperflexion and hyperextension occur separately or 
simultaneously on both legs or on only one leg. Poor muscle tone or deficiencies 
between the extensor and flexor muscles, excessive exercise, ligament 
deficiencies due to an excessive weight gain before adequate bone development 
and unbalanced growth may play a role in aetiology of the carpal laxity syndrome, 
but no alteration in mineral metabolism has been reported. This syndrome in 
puppies is frequently seen in rapidly growing medium, such as large and giant 
breeds. Sex was not identified as a risk factor. Carpal hyperflexion or 
hyperextension was not associated with pain in slight or severe forms. The intense 
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bone formation suggested by the increase of the plasma ALP activity would be 
associated with an increased mineral fixation, leading to a normalization of the 
plasma Ca and P concentrations. It would be also possible that a vitamin D 
deficiency would promote disequilibrium between bone formation and resorption. 
Vitamin D metabolites regulate the calcium metabolism and therefore skeletal 
development in dogs. These metabolites aid in the absorption of calcium and 
phosphorus from the gut, increase bone cell activity, and influence endochondral 
ossification and calcium excretion. (Atalan et al. 2009) 
Hyperflexion carpal syndrome is caused by the contracture of the flexor carpi 
ulnaris, The suspected diagnosis, based on the basis of signalament, medical 
history, general physical examination and orthopedic examination, the diagnosis 
is confirmed with radiographic examination. The disease, often self-limiting, has a 
favorable prognosis and a course generally short. The therapeutic approach can be 
expected, according to the severity and the clinical course, conservative or 
surgical measures. (Petazzoni & Mortellaro 2000) 
In foal, congenital flexural deformities have been attributed to a fetal malposition 
during intrauterine life. Also in this species other factors invoked are represented 
by skeletal abnormalities of the period accretion, genetic mutations, ingesting 
teratogenic substances as well as infectious diseases occurred during pregnancy. 
(Stashak T.S. 1987) 
Vaughan suggests the existence of a development asynchronous between skeletal 
tissue and tendon-muscular with greater growth of the first segment, due to a 
relative shortening tendon-muscular and consequently due to hyperflexion and 
hyperadduction carpal.  
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Dogs affected by SIC are generally very young (6-16 weeks of life) and they are 
of medium, large or giant size, the disease is reported in numerous breeds. The 
pathology is usually bilateral, although the two forelimbs  may be involved in 
different times and with varying severity; rarely can be also affected a single limb. 
The anamnesis does not report injuries. (Petazzoni & Mortellaro 2000) 
Bandage application was considered to be helpful to improve osteogenesis by 
diminishing constraints on bones and provided the shortening of the laxited flexor 
and extensor tendons. Although this syndrome may spontaneously be attenuated, 
some treatment methods such as balanced diet, moderate and appropriate 
exercises, the Robert Jones bandaging, splint, tenotomy and arthrodesis have been 
reported. (Atalan et al. 2009) 
 
◊ QUADRICEPS CONTRACTURES 
Quadriceps Contracture (QC) is a disease which is seen as a congenital deformity 
or as a complication of fractures of the femur in juvenile dogs. (Montgomery & 
Fitch 2003; Ulusan et al. 2011) This disease is also known as post-traumatic stifle 
joint rigidity, quadriceps tie-down syndrome, stifle joint hyperextension, hindlimb 
rigidity, quadriceps ischemic contracture or Sudek atrophy. QC has been reported 
as a complication from toxoplasmosis and neospora infection (Ulusan et al. 2011; 
Taylor J. & Tangner C. H. 2007) Factors that promote the likelihood of 
quadriceps contracture are age less than 6 months and splinting of the leg 
(especially in extension), although quadriceps contracture can develop without 
these factors. Contracture occurs over a period of weeks and, when complete, 
results in the stifle and hock locked in full extension. Most dogs with quadriceps 
 66 
contracture are not able to place the foot on the ground. Marked atrophy of the 
quadriceps is followed ultimately by general atrophy of the other muscle and the 
bone, typical caused by disuse. Treatment is effective only when implemented 
early and should be directed at early motion of the muscle and decreasing scar 
tissue during muscle healing. Salvage techniques include release of the quadriceps 
muscle group from proximal femur and pelvis, arthrodesis of the stifle and hock, 
and amputation. Arthrodesis and amputation are the only viable options when the 
condition is severe. (Montgomery & Fitch 2003)  
In case of infection by Neospora ot Toxoplasma the treatment consist in 
trimethoprim-sulfadiazine (TMS), and pyrimethamine. TMS at a dosage of 15 to 
20 mg/kg administered orally twice daily in combination with pyrimethamine at a 
dosage of 1 mg/kg/d is one treatment option. Alternatively, clindamycin at a 
dosage of 15 to 20 mg/kg administered orally twice daily, with or without 
pyrimethamine, is also recommended. Another possible combination therapy 
would be TMS and clindamycin at the dosages stated previously. Treatment 
should continue for 4 to 6 weeks. 
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EXPERIMENTAL STUDY 
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INTRODUCTION 
Myopathies can be classified as inflammatory or degenerative in nature. 
Inflammatory myopathies are the result of infiltration of inflammatory cells into 
striated muscle, with or without an association with an underlying cause. 
Inflammatory myopathies can be classified into two broad categories as seen in 
the list on the next page: idiopathic inflammatory myopathy (IIM) and secondary 
inflammatory myopathies associated with other diseases. Clinical signs for both 
types of inflammatory myopathy are related to the degree of inflammation, 
number and location of affected muscles, and presence of systemic disease. The 
ability to arrive at a definitive diagnosis for a successful therapeutic approach is 
dependent on early recognition of the clinical signs, appropriate diagnostic testing, 
and interpretation, followed by specific therapy either to immunosuppress the 
patient for IIM or to treat with anti-infective agent for infectious-induced 
myopathies. (Podell 2002) 
Inherited muscle diseases in dogs and cats are relatively uncommon and may be 
difficult to diagnose. It is important to obtain a correct diagnosis in these types of 
diseases because most occur in purebreds and knowledge of inheritance patterns is 
of utmost importance to animal breeders. A correct diagnosis is also important for 
animal owners, as the prognosis differs for the various muscle diseases. (Shelton 
& Engavall 2002) 
Standardized early examinations, comprehensive of serum creatine-kinase (CK) 
and metabolic investigations, neurophysiology (electromyography and nerve 
conduction velocity studies), neuroimaging (cranial ultrasonography and magnetic 
resonance imaging) and muscle or nerve biopsy of affected children is mandatory 
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to a better understanding of the underscored disorder and to begin the most 
appropriate therapy (Vasta et al., 2005). 
Aims of the study were to describe a case series of myopathies, in order to suggest 
a diagnostic algorithm and to verify the clinical usefulness of the muscular biopsy 
in the diagnostic iter. 
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MATERIALS AND METHODS 
This is a retrospective study in which we evaluate all the cases of myopathies 
referred  to the Department of Veterinary Medicine and Animal Productions of the 
University of Napoli Federico II from 2004 to 2014. We collected clinical cards 
listed on our computerized archiving system considering the species, breed, age, 
size and weight. As regards the history we focused especially on the timing of 
onset and then evaluating whether present from birth or later developed. At the 
same time we tried to assess whether clinical signs consistent with myopathy were 
the reason for the visit by the owner. So we performed the clinical examination 
and evaluation of the main symptoms that the animal showed. Most of the time 
the animals showed weakness, tremors, lameness, pain on muscles palpation. The 
diagnostic protocol proposed to the owners consisted of: complete blood count, 
serum biochemistry panel, evaluation of the IGG against Neospora and toxocara, 
urinalysis, radiographs, electrophysiologic evaluation and muscle / nerve biopsies. 
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RESULTS 
During the examined period, a total of 63 subjects were identified as affected from 
a neuromuscular disorder, two of which were cats (1,3%whereas the remaining 
were dogs (98,7%) (fig. 1). Considering a probability test with an equal frequency 
(50%) of neuromuscular disorders between the two species, the distribution 
resulted significantly different (P<0.0001). 
Figure 4 
 
 
Figure 4: Frequency histogram of the sample studied considering the species. 1     
The canine sample belonged to 25 different pure-breeds even if the most abundant 
portion belonged to mixed breed (28%). The two cats were European Shorthair. 
Male patients represented almost half of the sample (57%); when testing the 
probability of having a neuromuscular disorder independently of the sex, the 
difference was statistically significant (P<0.0001) (fig. 5). 
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The mean±SEM age of onset was 41±5 months (median 18 months; range 1-180 
months), even if the most of the neuromuscular disorders were recorded in the 
first year of life (50%) (fig.6). 
The most of the patients were large sized breeds (47%), and in fact the prevalence 
in such class resulted significantly more probable (P=0.002) (fig. 7). 
The most frequent cause for the owners to take their pet to be visited was 
weakness (33%), followed by lameness and deformity of one or more limbs (27%, 
both); trismus (6%), shivering (3%) or gastrointestinal/general symptoms (3%), 
i.e. vomiting, diarrhea and anorexia, were the least frequent reported signs (fig. 8). 
Clinical examinations revealed various signs, summarized in figure 9. 
EMG was performed in a small number of cases (13). No abnormalities were 
shown in the tested cases of polimyositis and MMM, except for a decrease of the 
insertional activity in presence of severe fibrosis. In the myopathy secondary to 
Addison disease no abnormalities were detected as well. In the case of neurogen 
myopathy associated to mitochondrial activity deficit, EMG showed an increased 
insertional activity at the vastus lateralis m. and at the tibialis cranialis ,  
fibrillation potentials (50 to  200 μV), sharp positive waves  (100 to200 μV),  
bizarre high-frequency discharges and at the right gastrocnemius m.. Nerve 
conduction velocity (NCV) was reduced (44,7 m/s). Decreases of NCV and 
occasional bizarre high-frequency discharges were the main features of 
neuromuscular pathologies and of the poliradicoloneuritis.  
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Histology resulted in a definitive diagnosis in 56 (71%) of cases. The most 
frequent pathology was neurogenic myopathy (30%), followed by inflammatory 
myopathy (14%), muscular dystrophy and aspecific myopathy (13%, both) (fig. 
10). In a single case (laxity ) the sampling was incorrect and only fascial tissue 
was collected . On the basis of clinical and histopatological data the following 
class of disease were diagnosed: neurogenic myopathy (14), focal myositis (2 
cases), polimyositis (10), MMM (5), metabolic myopathy (3), aspecific myopathy 
(2), traumatic myopathy (4), myasthenia (4), muscle dystrophy (4), mitochondrial 
myopathy (1), poliradiculoneuritis (1), swimming puppy syndrome (4), SIC (4), 
primary  quadriceps contracture (6).   
Focal myositis involved the proximal muscles of the left hind limb in one case and 
the quadriceps femoris m. in the other case. In the first case the pathology was 
associated to a sierological diagnosis of ehrlichiosis and the inflammation 
resolved after specific therapy (doxycycline 20 mg/kg die for 21 days). In the 
latter case an underlying cause was not identified and the symptoms partially 
regressed after non steroidal anti-inflammatory treatments and rest.  MMM, in one 
case was incompletely recognized, due to the prevalence of fibrotic tissue 
degeneration.  
Etiology of the polimyositis and of the radiculoneuritis remained uncertain in 
most cases. Four cases of polimyositis and 2 of MMM were associated to 
leishmania infection.  
Traumatic myopathies involved semitendinosus m. (1 case),  infraspinatus m. (1), 
pectoral muscles (1 case), adductor mm of the thigh (1 case) .    
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Metabolic myopathies were associated to Cushing syndrome in 3 case and to 
Addison disease in 1 case.    
MD was identified as alfa 2-laminin deficiency in two Great Danes, whereas 
dystrophy was not classified in two biopsies from an Akita Inu litter. In this case, 
muscle lesions were identified in the clinically healthy queen, and in one of four 2 
months old puppies. All the puppies showed severe weakness and amyotrophy. 
Immunohistochemistry failed to identify the deficiency of the tested proteins.  
Mitochondrial myopathy was diagnosed as main histopathological lesion in a 9 
years old cross breed dog, showing stiffness and exercise intolerance. 
Mitochondrial activity deficiency was associated to neurogen myopathy in a 5 
years old male fox terrier. In this case stiffness, exercise intolerance and shivering 
were the main clinical features and corticosteroid treatments was followed by the 
regression of symptoms, confirmed at a 6 months clinical follow-up.   
Aspecific myopathic changes were demonstrated in two cases of swimming puppy 
syndrome and in 2 case of SIC.  
Neospora canis was sierologically diagnosed in a case of quadriceps femoris 
contracture. In the other four cases sierological tests for Neospora canis and 
Toxoplasma gondii were negative and aspecific alterations were observed at the 
histological stains.  
Neither the histological nor the clinical diagnosis correlated with age of onset. 
Nonetheless, considering histological diagnosis (fig. 11), subjects affected by 
muscular dystrophy (mean 11 months old) were significantly younger (P=0.04) 
than patients with neurogenic myopathy (mean 84 months old). On the other hand, 
considering the clinical diagnosis (fig. 12), subjects affected by swimming puppy 
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syndrome (mean 1 month old), by carpal hyperflexion and hindlimb 
hyperextension syndrome (mean 9 month old, both) were significantly younger 
than both muscular atrophies (mean 72 months old) (P=0.04, P=0.04 and P=0.005, 
respectively) and pure post-traumatic myopathies (mean 158 months old) (P=0.01, 
P=0.03 and 0.009, respectively). 
 
Figure 5: Frequency histogram of the sample studied considering the sex. 
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Figure 6: Frequency histogram of the sample studied considering the age of onset. 
 
Figure 7: Frequency histogram of the sample studied considering the size. 
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Figure 8: Frequency histogram of the symptoms identified by owners. 
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Figure 9: Frequency histogram of the signs identified by at the clinical 
examination. 
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Figure 10: Frequency histogram of the histopathological diagnosis performed on 
muscle biopsies. 
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Figure 11: Box plots of age (months) considering the histopathological diagnosis. 
 
Figure 12: Box plots of age (months) considering the clinical diagnosis. 
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When considering the correlations between histological and anamnestic data, 
deformities resulted significantly associated with muscle dystrophy, shivering 
with mitochondrial myopathies and myasthenia gravis, trismus with masticatory 
muscles myositis (even if it was recorded also in inflammatory myopathy and in 
polymyositis) (P<0.0001) (fig. 13). 
 
Figure 13: contingency table evaluating correlations between anamnestic (x axis) 
and histopathological (y axis) data. 
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No specific correlations were found between histological and clinical diagnosis 
(P=0.68) (fig. 14). 
 
Figure 14: contingency table evaluating correlations between anamnestic (x axis) 
and clinical  (y axis) data. 
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Muscle dystrophy resulted over-represented in Akita Inu and Great Dane, and in 
both cases it was a familial form; myasthenia gravis was more frequent in Bull 
Terrier and Pointer; Focal myositis in Dalmatian; Masticatory Muscles myositis in 
Shar Pei (P=0.01) (fig. 15). 
 
Figure 15: contingency table evaluating correlations between breed (x axis) and 
histological diagnosis (y axis). 
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Considering the clinical diagnosis, Carpal Hyperflexion Syndrome was over-
represented in American Pitt Bull Terrier (P=0.003) (fig. 16).  
 
Figure 16: contingency table evaluating correlations between breed (x axis) and 
clinical diagnosis (y axis). 
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DISCUSSION 
Neuromuscular disorders are emerging pathologies in small animal clinic. A case 
series of 63 small animals affected by neuromuscular disorders is reported. The 
prevalence of dogs compared to the cat correspond to the literature data. Even if 
no study compares the prevalence of canine and feline neuromuscular disorders, 
literature about congenital and acquired diseases is wider and richer in dogs than 
in cats. However, it is  known that myopathies and neuromuscular disease present 
different etiopathogenetic and clinical features in the two species (Braund, 2006). 
Furthermore, disorders affecting motor neurons and nerve roots, peripheral 
nerves, neuromuscular junctions, and muscles can have a similar clinical 
appearance and in the cat, as well only in the dog, a complete diagnostic iter allow 
to obtain a precise diagnosis. (Ginman A. A. et al. 2009) Thus, conclusions of this 
study are referred exclusively to the dog and data cannot be extrapolated for other 
species.  
Congenital neuromuscular disorders are often described in specific breeds and a 
genetic basis is postulated for many of them (McGreevy J.W. 2015; Shelton G.D. 
2005; Ambrósio C.E. 2009; Broeckx B. J. G. 2013; Switonski M. 2014; Kornegay 
J.N. 2014). In this series, about a third of the cases are cross breed dogs, according 
to the population from which the group was extrapolated. In literature Evans et al. 
(2004) in a study of 200 cases of inflammatory myopathies Boxer and 
Newfoundland were overrepresented. MD is historically  related to Labrador 
Retriever (Bley T. 2002; Bergman R.L. 2002; Baroncelli 2014; Watson A.D. 
1988; Kommonen 1990;), but nowadays it is reported in different and always new 
breeds.  Other examples of congenital myopathies breeds related include: 
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mitochondrial myopathy,  reported in Clumber and Sussex spaniel (Herrtage E. 
1979; Houlton 1980), German Shepherd, Old English Sheepdog, Jack Russell 
Terrier and Labrador Retriever (Paciello O. 2003; Tauro A. 2008; Olby 1997); 
Congenital Myotonia, reported in Chow Chow, Staffordshire terrier, Great Danes 
and Miniature Schnauzer; Dermatomyositis,  reported in Shetland Sheepdog, 
Beauceron Shepherd, Pembroke Welsh Corgi, Australian Cattle dog, Lakeland 
terrier, Chow Chow, German Shepherd and Kuvasz. In some cases, specific 
myopathies are reported only in one breed, as for Bouvier des Flandres Myopathy 
(Braund 2006; Braund 1990; Peeters M.E. 1991). In these cases a genetic etiology 
or a breed predisposition is postulated. Specific mutations have been identified in 
CNM and XLMTM in Labrador Retrievers (Shelton 2010), whereas X-linked 
myotubular myopathy in Rottweiler dogs is caused by a missense mutation in 
Exon 11 of the MTM1 gene (Shelton et al. 2015) and 
Centronuclear myopathy in Labrador retrievers was correlated to a  mutation in 
the PTPLA gene (Maurer et al. 2012). Unfortunately, genetic molecular test are 
not easy available in practical sets and in this case series we cannot identify a 
genetic etiology in any case.  
However, in some cases similar clinical, electrophysiological and histopathologic 
features are shared with acquired diseases, described in adult mix-breed dogs. For 
example, myotonia is described as acquired disease, secondary to 
endocrinological disorders, such as Cushing disease and hypothyroidism. In this 
case no breed predisposition is reported (Braund K.G. 1980; Greene C.E. 1979; 
Rossmeisl J.H. 2009; Braund K.G. 1981). 
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Age of onset of our cases, is related to the disease prevalence as well. Swimming 
puppy syndrome, SIC, Quadriceps contracture and MD are obviously reported in 
puppies or in very young dogs. The clinical onset in a young dog of disease 
characterized by weakness, exercise intolerance and/or contracture should be 
considered suggestive of a congenital neuromuscular disorders. As above 
indicated, a complete diagnostic iter should be triggered in these cases,  whenever 
possible, on the basis of the owner consent and of the availability of diagnostic 
means.  
Blood chemistry showed a wide range of results, correlated to the variability of 
the underlying diseases. Sierological muscle markers were significantly raised 
only in few cases. CK, AST and LDH are considered sierological markers of 
muscle damage. The plasma half-life of CK is shorter than half-life of AST and 
serum AST increases are delayed by 36-48 hours after a muscle damage, when 
CK levels tend to normalize (Shelton 2010).  CK activity could be related to the 
nature of the diseases, but to their chronicity as well, and to the absence in many 
cases of acute fibers necrosis. Thus, due to the heterogeneity of this case series, a 
wide range of activity of the muscle markers was predictable. However, 
hematochemical analysis was useful in excluding or confirming metabolic and 
secondary myopathies and in monitoring therapy results. 
EMG and histopathology were proof to reveal a peripheral nervous system 
impairment probably due to a mitochondrial dysfunction in the 5 years old fox 
terrier. Electrophysiology was a useful mean to characterize or to exclude muscle 
and neuromuscular disorders, whenever was available.   It was shown that  EMG 
can give information about the extent and etiology of neuromuscular disease, but 
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that it has limited value in inferring clinical symptoms and neuropathic deficit, 
distinguishing between neuropathy and myopathy, inferring involvement of small-
diameter fibers, inferring underlying biochemical or other pathophysiologic 
derangement, inferring the presence and type of pathologic alterations in single 
fibers and Schwann cells, if not related to anamnestic, clinical and 
histopathological data. Despite these limitations, EMG is clinically useful in 
differentiating between denervation atrophy and disuse muscle atrophy. (van Nes 
1986; Cuddon 2002) 
Histopathology was almost always determining in the definitive diagnosis. The 
sample has to be correctly collected and sent to a specifically equipped laboratory. 
Biopsies of muscle, and in some cases peripheral nerve, should be collected early 
in the course of diagnostic evaluation of an animal with a neuromuscular disease, 
rather than waiting until extensive muscle damage, fiber loss, and fibrosis have 
occurred, when the chances for a successful treatment are diminished. Delay in 
diagnosis and initiation of appropriate therapy may result in irreversible fibrosis 
and limb contractures and fibrosis prevents in achieving useful diagnostic 
information about the primary disease. (Shelton 2010)  
Even if Labrador retrievers are considered an important animal model for human 
MD, complete antibodies panel for the immunohistochemical  diagnosis of canine 
dystrophies are expensive, not easily available and not always validated for this 
species. (Shelton, 2010) For these reasons, in our case series, some cases were 
classified as MD, on the basis of the histopathology, but not further defined. On 
the contrary, it was possible to obtain a definitive diagnosis for the two Great 
Danes puppies, affected by alfa2-laminin deficiency. This is the first documented 
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case of this disease in the dog (Trapani et al., 2010). It is interesting the 
correspondence between the severity of the clinical presentation and the 
expression of the antigen-antibody reaction at the immunohistochemistry, that was 
almost completely absent in the male dog, affected by a bilateral contracture of 
the quadriceps femoris m., associated to hydrocephalus and a severe blood-
coagulation deficiency. This dog was humanely euthanized. A less severe disease 
was shown by the female dog, with a corresponding better expression of the 
protein at the immunohistochemistry. Surgical correction of a unilateral hind limb 
contracture resulted in a favorable three years follow-up.  
Focal and systemic myositis were well represented in this case series and they 
were often related to very common infective disease, such as Leishmaniasis and 
Erlichiosis. Inflammatory myopathy associated with several 
infectious diseases occurs in dogs including those caused by Toxoplasma gondii, 
Neospora caninum, Ehrlichia canis and Hepatozoon canis. However, muscle 
disease due to Leishmania infection has been poorly documented. However it was 
demonstrated that, where Leishmania is an endemic disease,  it should be 
considered as a cause of IM in dogs. Leishmania is not present within muscle 
fibers but in macrophages, and that  the muscle damage might be related to 
immunological alterations associated with Leishmania infection. (Paciello et al. 
2009)  
In one case, Erlichiosis was related to a focal painful myositis and clinical 
remission result after tetracyclines therapy.  
Other causes of focal disease were traumas, reported by the owner at the history. 
In a case of semitendinosus m myopathy trauma was supposed as cause of the 
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muscle damage, but histopathology was suggestive of a neurogenic disease. 
Gracilis and/or semitendinosus myopathy has been reported sporadically in dogs, 
most commonly in male German Shepherds, with an age range from 8 months to 
9 years. The etiopathogenesis of the disease is unclear even if it is generally 
related to a muscle injury from excessive activity, that can lead to muscle strain, 
with a sequence of inflammation, edema, localized hemorrhage and, eventually, 
fibrosis. (Braund 2006; Lewis D.D. 1997; Pettit G.D. 1978; Bennet A.R. 1986; 
Moore R.W. 1981; Capello V. 1993) 
The examination of muscle biopsies, collected very early in the course of the 
disease could clarify the etiopathogenesis of this myopathy, that in human 
medicine is considered on a congenital basis or post-injective. (Gao G.X. 1988; 
Louis E.D. 1994; Van de Bergh 1997) 
SIC, contractural syndromes and laxity shared with neuromusculars disorders 
many clinical features. The biopsied cases in our series gave not conclusive 
results. Even if in some cases aspecific or specific alterations were demonstrated, 
it was not always possible to define if they were primary or secondary. However 
electrophysiological and istopathological examination of a large series of cases 
could allow a better understanding of these syndrome, that could be the clinical 
expression of etiologically different diseases.  
In conclusion, clinical, orthopedic and neurologic examinations allows to suppose 
a diagnosis of neuromuscular disorders. Whenever possible, in this cases only a 
diagnostic iter comprehensive of hematochemical analysis, electrophysiological 
examinations and biopsy is indicated to achieve a definitive diagnosis.  
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